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ABSTRACT
TRANSFERRIN‐BASED THERAPEUTICS AND ANALYTICAL METHODS TO CHARACTERIZE
THEM
MAY 2015
SON N. NGUYEN, B.A., VIETNAM NATIONAL UNIVERSITY, HANOI
M.A., VIETNAM NATIONAL UNIVERSITY, HANOI
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Professor Igor A. Kaltashov

Modern development of medicine requires detailed characterization by state‐of‐the
art analytical techniques that can be used to analyze covalent structure, conformations
and protein‐receptor interaction to quantitatively measure biodistribution of protein
therapeutics. Mass spectrometry has already become an indispensable tool facilitating
all stages of protein drug development. Particularly, this work has demonstrated the
tremendous potential of electrospray ionization (ESI) mass spectrometry (MS) in this
arena by providing invaluable information beyond mass measurement that can be used
to optimize protein drug conjugate structures during early stages of development, and
to further catalyze drug design efforts. Additionally, a new sensitive and selective
method that uses metal tracers and inductively coupled plasma (ICP) MS developed in
our lab has been successfully applied for quantitating exogenous transferrin (Tf) and Tf‐
based drugs in biological tissues and fluids. Furthermore, ICP‐MS based method using
metal tracer in combination with size exclusion chromatography (SEC) method proved
to be able to probe into protein stability post‐injection and to yield useful data not
vii

accessible by other methods. For the first time a small soluble protein aggregation of
injected protein drug was studied in live animals. Finally, a simple and cost‐effective 18O
labeling‐based method has been developed for quantitating lysine modification sites of
protein drug conjugates and has been successfully applied for N‐succinimidyl‐S‐
acetylthioacetate (SATA)‐Lysozyme (Lz) conjugate.
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CHAPTER 1
INTRODUCTION
1.1.

Biopharmaceuticals

1.1.1. General
Biopharmaceuticals, also known as biologics, which are distinct from chemically
synthesized pharmaceutical products, generally refer to medicinal products
manufactured in or extracted from biological sources.1 Vaccines, blood and blood
products, allergenic extracts, human cells and tissues, gene therapies, cellular therapies

and recombinant therapeutic protein are among examples of biopharmaceuticals.
Thanks to their excellent features such as high specificity and activity at relatively low
concentrations, biopharmaceuticals have become the fastest growing segment among
the new pharmaceutical products.2
Nowadays, biopharmaceuticals extracted from natural sources continue to be used
for diverse diseases. Modern drug manufacturing processes, however, have limited this
need thanks to the improvement in production and safety from recombinant DNA
technology.3 There are 91 recombinant‐protein‐based new molecular entities (NMEs)
have been approved by the FDA as therapeutics since the first biologic was approved
(Table 1.1).4 Three major categories of biologics include: monoclonal antibodies,
enzymes replacement/modulators and cell surface receptor function replacement/
modulators.
Receptor modulator. These are substances that are identical to human key signaling
proteins. Examples of these are the biosynthetic human insulin and its analogues and
1

growth hormone. Initially, insulin was extracted from animals’ pancreas, however, due
to medical need and safety, recombinant insulin proved to be a very good alternative. In
1982, Eli Lilly’s recombinant human insulin produced in E. coli was the first biologic
approved.5 This approval helped open the door for the production of biologics by this
technology.
Enzyme modulator. Enzyme modulators are used to replace enzymes which are
deficient or absent in patients.6 This medical treatment is currently available for
lysosomal diseases such as Gaucher disease, Fabry disease, etc.7 It is important to note
that, although enzyme replacement therapy can greatly modify or reduce the
symptoms and severity of the condition as well as disease progression, it does not cure
these disorders.8
Monoclonal antibodies. “Custom‐designed" antibodies are similar to those in the
human immune system that can target any specific cell type or counteract or block any
given substance in the body. The first approved monoclonal antibody, muromonab CD3,
was a murine protein used in acute organ transplant rejection.9 However, minimizing
immunogenicity was not possible until the approval of the second monoclonal antibody,
abciximab (1993), in which complementarily‐determined regions were replaced by the
human version.10 Currently, technologies enhancing drug safety and efficacy continue to
advance alongside the fully human antibodies.4
1.1.2. Second generation (engineered) biopharmaceuticals

2

Unlike the first generation, often refers as “replacement proteins”, the second
generation biologics are engineered in ways to control their activity.11 These include
covalent surface modification with polyethylene glycol (PEG), alteration of glycosylation
and amino acid sequence, or protein‐protein conjugation.
PEGylation and fusion protein. Small biologics that are less than ~60kDa are likely to
be cleared from the body via glomerular filtration12. In order to extend the circulation
half‐life of protein‐drugs, their hydrodynamic size can be increased by covalently
modifying the surface with hydrophilic polymers such as polyethylene glycol13, sialic
acid14, polysaccharides hyaluronic acid15 and hydroxyl ethyl starch.12
Other approaches exploiting the FcRn recycling process by genetically fusing protein
drugs with the Fc region of IgG have also been used to prolong drug circulation half‐life.
The blockbuster etanercept (Enbrel; Amgen) is one of these.
Protein‐drug conjugation. Protein‐drug conjugates are very promising approach for
cancer treatment. They combine the carrier proteins’ specificity with the potency of
cytotoxic drugs, thus, having the best features of both components. Carrier proteins,
such as monoclonal antibodies (mAbs) or other transport proteins such as transferrin
(Tf), can be linked to cell‐killing drugs via various chemical linkers. Following the
guidance, binding of carriers to target cancer cells and the internalization of the protein
conjugates, the toxic drugs can be chemically and/or enzymatically released and
activated to kill the cells.16 The success of the targeted delivery approach depends upon:
(1) the characteristics of the carrier, (2) the potency of the drug, and (3) the method of

3

linkage of the carrier to the drug. Table 1.2 shows key parameters for protein
conjugates.17‐31
Conjugation chemistry. Due to the long exposure of protein‐drug conjugates,
normally several days post‐injection, it is very important that the drug‐linker is stable. It
is reported that protein‐drugs linked via disulfide and hydrazone linkers are not as stable
in circulation compare to those using protease‐cleavable linkers.

22‐24

The three most

common methods for protein‐drugs conjugating include: lysines and cysteines
conjugation (either from reduced interchain disulfides or by addition of genetically
engineered cysteines). Due to the abundance of lysine residues (up to 100 on IgG1
mAbs), cysteine‐based conjugates are more uniform than that of lysine‐based
conjugates29. However, to some extent, the number of drug molecules attached is more
important than the location.29, 31 For example, it was reported that a maximum of four
drug molecules, depending on their size, to one carrier protein usually circulated longer
and was found to be superior to those more heavily loaded.28
1.1.3. Transferrin and its potential as a drug carrier
Transferrin (Tf) is a promising drug carrier that has the potential to deliver metals,
small molecule medicines and therapeutic proteins to cancer cells32 and/or across
physiological barriers (such as the blood‐brain barrier, BBB33). Despite this promise, very
few Tf‐based therapeutics have been developed and/or reached clinical trials.
Most of the earlier explorations of Tf as a potential delivery vehicle focused on
intracellular drug delivery. Various therapeutic agents such as metal ions,

4

chemotherapeutics, proteins drugs, genes and nanoparticles have been coupled to Tf
for tumor specific targeting.34‐39 For example, 67Ga3+ and 111In3+ were found to be able to
replace Fe3+ ions in Tf molecules and have been used as a diagnostic technique for many
malignancies.40 In another example, artemisinin tagged holo‐Tf was used as a cancer
targeting therapeutics, thanks to the free radicals released when it reacts with iron.41
Notably, a diphtheria toxin (DT) point mutant, CRM107, has been conjugated to Tf and
tested for the treatment of malignant brain tumors. This is the only Tf‐based conjugate
that has reached clinical trials before being discontinued at phase III.42
As one of few proteins that have the ability to cross physiological barriers, Tf has
also been exploited to target difficult‐to‐reach intracellular targets.43‐47 Recently, an
animal model study has showed the successful BBB‐crossing of a Tf‐human serum
albumin nanoparticles conjugate. Additionally, in our group, we have explored the
properties of Lysozyme (Lz) conjugated to Tf as a model therapeutic that targets the CNS
and develop analytical protocols to characterize its structure and interactions with
therapeutic targets and physiological partners critical for its successful delivery.48
1.2.

Experimental methods to characterize biologics

1.2.1. Separation‐based methods
Size exclusion (gel filtration) chromatography (SEC) separates biomolecules purely
based on their hydrodynamic size differences rather than interaction with stationary
phase. Analytes of different size diffuse differently through a SEC column containing
pore size controlled particles. Due to the ability to diffuse freely into the pores, small

5

molecules tend to elute from the column later than the larger one. Thus, analytes are
separated in order of decreasing hydrodynamic sizes which, in most cases, are
proportional to their molecular weights. SEC is a low resolution separation technique. It
is, therefore, normally applied for fractionation (purification or characterization) or
group separation (desalting or removing low‐molecular‐weight contaminants).49
Ion‐exchange chromatography (IXC) separates biomolecules on the basis of their
charge differences. IEX have the ability to resolve identical proteins that differ by only a
single charged group.50 Typical charged groups on biomolecules that form ionic bonds
with the stationary phase ligands are –NH3+, =NH2+, ≥NH+, –COO–, PO4–, SO32–. After
removing the non‐bound species by washing, bound biomolecules are eluted with either
a higher ionic strength or altered pH buffer. It is a high resolving power technique with
fast separations, high recovery and most importantly it can retain biological active form
of proteins even though the samples may contain high salt concentrations (>1 M).51
Reversed‐phase liquid chromatography (RP‐HPLC) separates different analytes from
the mobile phase on the basis of their hydrophobic binding to the ligands attached to
the stationary phase. Analytes will be eluted in order of increasing molecular
hydrophobicity using either isocratic or gradient elution. For the analysis of peptides and
proteins, RP‐HPLC is a very powerful technique due to its excellent resolution even for
very closely related molecules along with high recoveries and excellent reproducibility.50
Unfortunately, biologically active form of proteins may not be recovered with this
technique due to the use of high organic content solvent causing irreversible
denaturation.49
6

Field‐flow fractionation (FFF) is a family of chromatography‐like elution techniques
first described 196652 which separates molecules in a single liquid phase with the help of
an external field applied orthogonally to the flow direction.53 It can be applied for a wide
colloidal size range of analytes from proteins, supramolecular assemblies to colloids and
particles.54 A broad range of external fields were used including cross‐flow stream
(FlFFF), temperature gradient (ThFFF), electrical potential (ElFFF), centrifugal force
(SdFFF), gravitational force (GrFFF), dielectrophoretic (DiFFF), standing acoustic wave
(AcFFF) and magnetic fields (MgFFF).55 Of these techniques, flow FFF (FlFFF), has been
the most popular FFF method applied for protein separation and analysis due to its
ability to separate intact proteins within ~105 mass range in a single run.56
Capillary electrophoresis (CE) is the most efficient family of separation techniques
that is available for the analysis of both large and small molecules.57 It separates
analytes based on the differences in electrophoretic mobility which relates to their
charge, size and viscosity when applying a high voltage electric field over a sample in
buffer solution held in a silica capillary.58 Of all techniques in its family, capillary zone
electrophoresis (CZE) that moves analytes via electroosmotic flow (EOF) and separates
them based on mass‐to‐charge ratio is the most commonly used. In most cases,
changing the pH will manipulate the separation thanks to the pH dependence of
analytes’ charge.59 For CZE separation of basic proteins, however, the fused silica’s wall
need to be modified so that silanol groups are no longer exposed, thus, preventing the
absorption of the proteins being analyzed.60
1.2.2. Mass spectrometry
7

Mass spectrometry (MS) has become an indispensable tool for characterizing
biological macromolecules. It provides sensitive and accurate measurements for a wide
variety of molecules and complex mixtures of biomacromolecules by the separation and
characterization based on ions mass‐to‐charge ratio (m/z). Mass spectrometry (MS) not
only allow characterizing the covalent structure of biomolecules but also at a wide range
of levels, including conformation, dynamics and interaction with physiological
partners.61, 62
Primary structure. The MS methods for identifying amino acid sequences and post‐
translation modifications (PTMs) of proteins have been extensively reported.63,

64

Although those MS methods depend on PTMs and the availability of MS
instrumentation, in most cases, either intact proteins (“top‐down”) or enzymatic
digestion approach (“bottom‐up” or “peptide mapping”) was involved. Due to the
presence of salt and/or others MS incompatible matrix components, HPLC is commonly
used with MS for the analysis. Moreover, in order to analyze proteins from cell culture
supernatants, an additional “capture” step (e.g., affinity chromatography) may be
required.65
Native electrospray mass spectrometry (ESI‐MS) is the key to preserve protein
higher order structures which enables the study of protein conformation and dynamics.
In ESI‐MS, the use of “volatile buffers” is necessary since most buffer solutions that are
used in structural biology are not ESI‐MS compatible and may interfere with the protein
ionization. Those compatible buffers include ammonium acetate (NH4Ac) and
ammonium bicarbonate (NH4HCO3) with neutral pH and concentrations ranges from
8

5mM to 1M. Under these conditions, it is well known that quaternary protein structures
can often be preserved.61,

62, 66

It is also worthy to note that, native ESI‐MS volatile

solvents usually generate less charged ions than those in organic ESI solvents because
the surface of the folded species is more compact.67
Hydrogen deuterium exchange mass spectrometry (HDX MS). Protein HDX studies
focus on hydrogens that are located at main chain amides since they represent a
continuous structural probe covering the entire protein chain. The HDX patterns of the
amide hydrogens are affected by protein flexibility and mobility, thus, making HDX an
extremely sensitive probe of protein structure and stability. HDX MS is a reliable, robust
and sensitive technique as well as being a very promising technique for characterizing
the conformation of protein drugs thanks to its ability to detect structurally
compromised proteins in the background of the natively folded species in highly
complex matrices.68
1.2.3. Experimental methods for pharmacokinetics (PK) studies
Enzyme‐linked immunosorbent assay (ELISA) is a sensitive and versatile method for
both detection and quantitation of either antibodies or many antigens including
viruses69, hormones70, peptides71, and proteins.72 This immunological assay method is
one of the most popularly used that can be applied for both single sample analysis and
high‐throughput screening thanks to its simple protocol. Principally, ELISA involves the
specific binding of antibody to antigen with one of them immobilized to a solid support.
The enzyme‐conjugated antibody followed by a chromogenic substrate is used to
amplify and visualize the binding activity.73
9

Radiotracer. Radioisotopes of elements such as carbon74,

75

, titanium76, gallium77

iodine78 and indium79 have been widely used for pharmacokinetic studies as well as
tracking the distribution of biopharmaceuticals in cells or tissues. The radiotracer
method is based on the idea that all isotopes of the same element will have the same
chemical properties. Therefore, instead of detecting non‐radioactive isotopes, it is far
easier to follow the radioactive one in the complex matrix due to the high sensitivity and
selectivity of this approach. However, the routine use of this method is hampered
because of the health and safety issues over handling of radioactive compounds as well
as the disposal costs.80
MS‐based methods to study pharmacokinetics of protein therapeutics.
Pharmacokinetics of any drug, being traditional small molecule medicines or
biopharmaceuticals, is one of the factors that decides its clinical success along with the
ability to interact specifically with a desired therapeutic target.81 MS‐based protein
quantitation methods have dramatically expanded the scope in pharmacokinetic studies
of protein drugs.82 For accurate and reliable quantitation of proteins, a stable isotope
labeled internal standard is normally introduced in order to compensate for the matrix
effect of the LC‐MS measurements. The internal standard can be introduced at the
protein level or at the peptide level. Undoubtedly, a protein‐based internal standard is
superior to a peptide‐based method due to the fact that the errors associated with
downstream sources can effectively be removed or compensated for. Stable isotopes
used to label internal standard include 15N (whole protein labeling)83, 13C (partial protein
labeling,

13

C6‐Arginine and

13

C6‐Lysine)84,

18

O (protein labeling:

10

18

O‐cysteine85, ICAT86;

peptide labeling:

18

O‐Arginine and

18

O‐Lysine87). Among them,

18

O based methods are

usually more attractive due to the relative ease and universality of labeling.
Inductively coupled plasma (ICP) MS and its potential for protein quantitation. ICP
MS is a very powerful technique for elemental analysis88‐90 that can be applied for the
detection of metal‐ and metalloid‐containing compounds.91, 92 It relies on a hot argon
plasma to break down compounds in homogenous solution into atoms of elements and
eventually ionize them before introducing to a mass analyzer. This method is extremely
sensitive toward metals due to their low ionization potential compare to other
elements, i.e. halogen, thus, it is widely used for the quantitation of metals. In the last
several years, ICP‐MS has been applied in a many different areas, particularly
bioanalysis93. Indeed, ICP‐MS provides an excellent alternative method for absolute
protein quantitation via metal labeling strategy due to the high sensitivity and selectivity
of the method. The most commonly used metal tags are the chelates of lanthanides due
to their absence in biological samples, which mean that there is no spectroscopic
interferences and a very low background signal. Furthermore, metal tagged protein
drugs also enable the biodistribution study at the cellular level by imaging laser ablation
(LA)‐ICP‐MS. Over the last few years, imaging LA‐ICP‐MS for the analysis of biological
samples has been widely used94‐98 i.e. cisplatine treatment in kidney99,

100

,

selenoproteins detection in gels101, distribution of heavy metals in plants102, or using 31P
to indentify tumor boundaries in lymph node biopsies103.
1.3.

Objectives
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Modern medicine development and detailed characterization requires state‐of‐the
art analytical techniques that can be used to analyze covalent structure, conformations
and protein‐receptor interaction for quantitative measuring biodistribution of protein
therapeutics. Mass spectrometry has emerged as a powerful tool for these
measurements. My work consists of multiple projects aiming to develop mass
spectrometry based analytical protocols to assist the optimization and characterization
of transferrin‐based conjugates as well as tracking and constructing their distribution
maps in vivo. Specific aims include: (i) exploring the properties of an Lz‐Tf conjugate as a
model therapeutic that targets the CNS and develop analytical protocols to characterize
its structure and interactions with therapeutic targets and physiological partners critical
for its successful delivery (Chapter 1); (ii) In‐vivo studies of the biodistribution of
transferrin‐based drug in animal models by inductively coupled plasma mass
spectrometry (ICP‐MS) (Chapter 3); (iii) study of in‐vivo aggregation of transferrin‐based
drug by size exclusion chromatography (SEC) and inductively coupled plasma mass
spectrometry (ICP‐MS) (Chapter 4); (iv) development of an 18O labeling based method to
quantitatively map the modification sites of protein‐drugs conjugates (Chapter 5).
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TABLES
Table 1.1. Comparison of small molecule and biologic‐based new molecular entities
(NMEs) (1982–2013).4
NME type

Total

IND to approval (years)

Withdrawn (safety concerns) (%)

Small molecule

777

8.5 (n = 200)

26 (3.3%)

Biologic

91

7.4 (n = 30)

2 (2.2%)

Monoclonal antibody

34

7.8 (n = 18)

2 (5.9%)

Enzyme modulator

26

5.9 (n = 8)

0

Receptor modulator

31

8.3 (n = 4)

0

IND: the average times from investigational new drug to approval

Table 1.2. Key parameters for protein conjugates17
Parameter

Description

Leading examples

References

Antigen/

Substantial expression on tumor,

Her2, CD30, CD33

18‐21

Receptors

limited expression on normal tissues

Linker

High stability to avoid systemic

Dipeptides, direct

22‐24

release

linkage, some
hydrazones and
disulfides

High potency since delivery is limited

Auristatins, maytansines,

by antigen copy number

calicheamicin

Drug

Maintain mAb PK by limiting drug

2‐4 drugs per mAb often

loading level

loading

optimal

Conjugation

Homogeneous drug loading by site‐

Chemical

site

specific conjugation to avoid

methods,cysteine point

subpopulations with altered PK

mutants

Drug
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25‐27

28
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ABSTRACT
Transferrin is a promising drug carrier that has the potential to deliver metals, small
organic molecules and therapeutic proteins to cancer cells and/or across physiological
barriers (such as the blood‐brain barrier). Despite this promise, very few transferrin‐
based therapeutics have been developed and reached clinical trials. This modest success
record can be explained by the complexity and heterogeneity of protein conjugation
products, which also pose great challenges to their analytical characterization. In this
work, we use lysozyme conjugated to transferrin as a model therapeutic that targets the
central nervous system (where its bacteriostatic properties may be exploited to control
infection) and develop analytical protocols based on electrospray ionization mass
spectrometry to characterize its structure and interactions with therapeutic targets and
physiological partners critical for its successful delivery. Mass spectrometry has already
become an indispensable tool facilitating all stages of the protein drug development
process, and this work demonstrates the enormous potential of this technique in
facilitating the development of a range of therapeutically effective protein‐drug
conjugates.
KEYWORDS
Biopharmaceuticals; drug delivery; protein‐drug conjugate; protein cross‐linking; ion
exchange chromatography; electrospray ionization; mass spectrometry; protein‐
receptor binding; enzyme‐substrate binding
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2.1.

Introduction

Transferrin (Tf) is a promising drug carrier that has the potential to deliver metals,
small molecule medicines and therapeutic proteins to cancer cells32 and/or across
physiological barriers (such as the blood‐brain barrier, BBB33). Despite this promise, very
few Tf‐based therapeutics have been developed and reached clinical trials. This very
modest success record can be explained by the complexity and heterogeneity of protein
conjugation products, which also pose great challenges to their analytical
characterization. Possible interaction of the therapeutic payload with the carrier protein
may have a negative impact on the conformational stability of the latter. Even in the
absence of such interactions, the mere presence of the conjugate on the protein surface
may sterically interfere with the ability of Tf to associate with its receptor at the cell
surface, a critical first step in the drug delivery scenarios. Another complication arises
due to the need to either have an effective mechanism of liberating the payload from Tf
inside the endosome (in order to allow its routing to the intracellular target as opposed
to recycling it back to the cell surface), or ensuring that it still exerts its therapeutic
action while being attached to Tf if the latter is intended to ferry the payload across a
physiological barrier, such as the BBB.
While most of the earlier explorations of Tf as a potential delivery vehicle focused on
intracellular drug delivery,34‐39 its ability to cross physiological barriers may also be
exploited

to

target

difficult‐to‐reach

intracellular

targets.43‐47

For

example,

neuroanatomical obstacles frequently limit the effectiveness of antimicrobial therapy in
the central nervous system (CNS) by preventing a large number of effective
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antimicrobials from reaching sufficient concentration levels at the infection site.104
Furthermore, the ever increasing number of bacterial pathogens resistant to common
antibiotics has brought to the fore the question of whether the repertoire of
antimicrobials should be expanded beyond classical small molecule drugs (be they
natural or synthetic products) by considering larger bio‐inspired host defense systems,
such as amphiphilic peptides105 and other bacteriostatic macromolecules. One
particularly attractive class of such bacteriostatic agents is a group of enzymes that
compromise the integrity of bacterial cell walls.106 Lysozyme (Lz) is an antibacterial
enzyme present in a variety of organisms, which exerts its bacteriostatic function by
hydrolyzing the β‐1,4‐glycosidic bond between the N‐acetylmuramic acid (NAM) and N‐
acetylglucosamine (NAG) residues of peptidoglycans, resulting in lysis of bacterial cell
walls. Although Lz primarily attacks Gram‐positive bacteria, where the peptidoglycan
layer is not protected by the outer membrane (as it is in Gram‐negative bacteria),
certain structural modifications can make it effective against Gram‐negative bacteria as
well.107
While Lz is widely distributed throughout the human body, it is not present in the
cerebrospinal fluid (CSF) of healthy subjects108 (detectable levels of Lz in CSF is usually
associated with various CNS pathologies109,

110

and are likely to reflect increased

permeability of the BBB110). Therefore, the ability to deliver Lz “on demand” across the
BBB might lead to development of novel effective therapeutic strategies aimed at the
eradication of Gram‐positive infections in the CNS, whose carriers gain access to the
brain via a variety of routes.104
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In this work we explore the properties of Lz conjugated to Tf as a model therapeutic
that targets the CNS and develop analytical protocols to characterize its structure and
interactions with therapeutic targets and physiological partners critical for its successful
delivery. We demonstrate that electrospray ionization (ESI) mass spectrometry (MS)
provides a convenient and effective way to probe both the structure of the conjugation
products and their ability to interact with physiologically and therapeutically relevant
partners, thereby providing important and valuable feedback that that can be used to
refine and optimize the conjugation protocols and greatly facilitate the early stages of
the drug development process.
2.2.

Experimental

Preparation of Lz‐Tf conjugate. For each reaction the optimal final conditions are
given in the text while various reaction parameters tested during optimization are listed
in parenthesis. Lz from chicken egg white (Sigma‐Aldrich, St. Louis, MO) was activated
(decorated with free thiol groups) using either Traut’s reagent (2‐iminothiolane
hydrochloride; Sigma‐Aldrich, St. Louis, MO) or N‐succinimidyl‐S‐acetylthioacetate
(SATA; Pierce Biotechnology, Rockford, IL), which target primary amine groups.111 The
reaction was carried out by incubating 12 h (0.5, 0.75, 1, 2, 12, 24 h) at 0 oC (0, 4, 25, 37
o

C) in 50 mM phosphate buffer with 100 mM NaCl pH 8.0 (7.0, 7.5, 8.0, 8.5, 9.0) and

consisted of 500 µM (50, 100, 250, 500 µM) Lz with a 1:1 ratio (2:1, 1:1, 1:2, 1:4) of
primary amines relative to the thiolating reagent (freshly prepared in H2O).
Incorporation of thiol‐reactive maleimide groups into human Tf (provided by Prof. Anne
B. Mason, University of Vermont College of Medicine) was carried out by reacting with
19

either

sulfosuccinimidyl‐4‐[N‐maleimidomethyl]

cyclohexane‐1‐carboxylate

(sulfo‐

SMCC: Pierce Biotechnology, Rockford, IL) or succinimidyl‐([N‐maleimidopropionamido]‐
dodecaethyleneglycol) ester (SM(PEG)12; Pierce Biotechnology, Rockford, IL) for 90 min
(30, 60, 90, 120 min) at 25 oC (4, 25, 37 oC) in 50 mM phosphate buffer with 100 mM
NaCl pH 7.0 (6.0, 7.0, 8.0, 9.0) and consisted of 250 M (50, 100, 250 M) Tf with a 1:2
(1:2, 1:4, 1:20) ratio of Tf relative to the activating reagent (freshly prepared in DMSO).
Excess activation reagents were removed by centrifugal filtration through a 10 kDa
Vivaspin molecular weight filter (Sartorius Stedim Biotech SA, Bohemia, NY) and the
non‐cleavable thio‐ether linkage between activated Lz and Tf was formed by incubating
50 M (25, 50, 100 M) each of the two modified proteins together for 12h (1, 2, 4h, 12,
24h) at 4oC (4, 25, 37 oC) in 50 mM phosphate buffer with 100 mM NaCl, pH 7.0 (7.0, 8.0,
9.0) at 1:1 molar ratio. The 1:1 Lz‐Tf conjugate was isolated by cation exchange
chromatography on a 4.6 x 100 mm PolyCATA™ column (5 µM, 1000 Å, PolyLC Inc.,
Columbia, MD) using an Agilent 1100 (Agilent Technologies, Palo Alto, CA) HPLC system.
All relevant reaction diagrams are shown in Figure 2.2.
Mass spectrometry. All ESI MS measurements were carried out with a QStar‐XL
(ABI/SCIEX, Toronto, Canada) hybrid quadrupole/time‐of‐flight MS equipped with a
nanospray source. Mass profiling of activated Tf, activated Lz, the crude reaction
product mixture, and the 1:1 conjugate isolated by cation exchange LC was carried out
following

extensive

buffer‐exchange

of

proteins

and

placing

them

in

water/methanol/acetic acid (49:49:2) at a concentration of ca. 10 µM. Native ESI MS
analyses of the conjugate, and its mixtures with TfR and NAG3 were performed using 20
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mM ammonium acetate as a solvent. To ensure the integrity of non‐covalent complexes
in the gas phase, the declustering potential in the ESI MS interface (DP1) was minimized,
unless noted otherwise in the text. Ectodomain of transferrin receptor (TfR)112 used in
binding assays was provided by Prof. Anne B. Mason (Univ. of Vermont College of
Medicine, Burlington, VT), and N‐acetylglucosamine trimer (NAG3) was purchased from
Sigma‐Aldrich (St. Louis, MO).
Antimicrobial activity assay. Antimicrobial activity of intact Lz, Lz dimers and Lz‐Tf
conjugate was measured using re‐suspended dried cells of Micrococcus lysodeikticus
(Worthington Biochemical Corp., Lakewood, NJ) as the substrate. The rate of cell wall
lysis in 0.1 M sodium phosphate buffer pH 7.0 at 25°C was monitored by recording the
transmission at 450 nm.113 The measurements were carried out in a 1 mL cuvette with a
NanoDrop 2000c (Thermo Fisher Scientific, Rockford, IL) UV‐Vis spectrophotometer.
2.3.

Results

2.3.1. Production, purification and characterization of the Lz‐Tf conjugate
The classical scheme of conjugating Tf to a protein payload involves derivatizing the
Lys side chains and amino terminus of Tf with sulfo‐SMCC and activating the protein
payload at similar sites using Traut’s reagent, followed by reacting them with each
other114. This produces the same thio‐ether linkage that was used in the production of
TransMID,115 the only Tf‐based biopharmaceutical product that ever reached Phase III
clinical trials. It is expected that a 1:1 stoichiometry for the conjugate would minimally
disturb the functionality of either molecule and was the desired product of our
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synthesis. Placing a single maleimide group on Tf and a single free thiol group on Lz
should lead to the formation of a 1:1 conjugate, with Lz dimers being the only by‐
product that can form via external disulfide bond formation (Figure 2.2). While the
extent of Tf functionalization with sulfo‐SMCC and Lz with Traut’s reagent can be varied
over a wide range it is virtually impossible to limit the extent of activation of the two
proteins to a single reactive group on each polypeptide chain (Figure 2.2). Moreover,
with 58 Lys residues in Tf and 6 in Lz, an additional level of heterogeneity is introduced
by the number of linker positions that can form a 1:1 conjugate. Our initial development
embraced this possible heterogeneity, benefitting from a quicker development time.
Identifying conjugation sites would be suited for final optimization of the protein drug
conjugate.
We found that adequate yields of the conjugation reaction can be achieved only if
multiple activation groups are placed on each protein. Placing multiple free thiol groups
on Lz is likely to increase the incidence and extent of this protein’s polymerization via
formation of external disulfide linkages. While homo‐polymerization of the
functionalized Tf was not expected to be as significant (at neutral pH maleimide groups
are ca. 1000 less reactive towards free amines compared to free sulfhydryls), this
process nonetheless was found to occur. Homo‐polymerization was particularly
apparent when concentrations of Tf in the reaction mixture were elevated compared to
that of the activated payload (Lz), most likely due to the presence of a large number of
free amine groups (Lys side chains) on the surface of Tf. Above and beyond the
formation of Lzn (and, to a lesser extent, Tfn) homo‐polymers, polyvalent
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functionalization of Tf and Lz was also expected to contribute to the extent of
heterogeneity of the conjugation products (Figure 2.2C). Balancing the extent of
modification of each protein in order to optimize production of the 1:1 Lz‐Tf conjugate
was achieved in this work by controlling the following primary variables: reagent
concentrations, temperature, incubation time and reaction pH. Mass spectrometry
enabled us to determine the effect of altering these variables on the product, allowing
us to screen these parameters in an iterative fashion that sought to optimize the yield of
conjugation while minimizing undesirable side reactions.
Of the two modification reactions, thiolation by Traut's reagent was the most
problematic. Two significant issues that needed to be overcome were the reduction of
intramolecular disulfide bonds and formation of N‐substituted 2‐iminothilane (NSI)
products. The abundance of intramolecular disulfide bonds within Tf presented an
unexpected obstacle when this protein was initially chosen for activation by Traut’s
reagent. While the highest yield of thiolated Tf could be obtained at elevated pH and a
high concentration of reagents, the native disulfide bonds of Tf were largely reduced,
leading to a drastic and unacceptable change in its higher order structure (see
Supporting Information Figure S1 for more detail). Disulfide reduction was still
observed (albeit to a much lesser extent) in the thiolation of Lz by Traut’s reagent, but
was practically eliminated by reducing reagent concentrations and performing the
reaction on ice. Further investigation of this reaction led us to an interesting finding; In
addition to thiolated proteins, other chemical modifications were observed with masses
consistent with non‐thiol by‐products reported by Singh.116 These dead‐end (non‐
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reactive) products form when the unstable thiol adduct breaks down into a non‐reactive
5‐membered ring and reduce the number of free thiol groups. Such instability in one of
the activating groups can significantly hinder downstream conjugation even when all six
Lys residues of Lz have been functionalized (Figure 2.3B). Formation of NSI by‐products
was also observed during and after the conjugation reaction, but fortunately could be
minimized by lowering the reaction pH and temperature. We investigated the use of N‐
succinimidyl S‐acetylthioacetate (SATA) as an alternative reagent to introduce the
desired thiol group. SATA introduces a “protected sulfhydryl” which requires activation
by a mild reducing reagent to expose the sulfhydryl prior to the conjugation reaction.
Compared to Traut’s reagent, Lz functionalized with SATA had increased stability (did
not form NSIs) and reduced heterogeneity (Figure 2.3B,D).
Optimizing the activating steps for each protein focused initially on minimizing
deleterious or non‐productive by‐products such as the reduction of intramolecular
disulfide bonds or the formation of NSIs as monitored by ESI MS. After screening pH
values from 7.0 to 9.0, reaction temperatures from 0 to 37oC, and reaction times from
0.5 to 24 hours, the optimized thiolation reaction was performed at pH 8, 0oC, for 12 h.
Notably, in the examined range of protein concentrations (50 µM to 500 µM), elevated
protein concentration was found to result in a higher yield of modified Lz. Different
ratios of protein primary amine to reagent from 2:1 to 1:4 were used to generate a
series of differentially modified Lz. The optimal extent of Lz activation was determined
in conjunction with the optimal extent of Tf activation selecting for values that produced
the highest yield of the 1:1 Lz‐Tf conjugate. The final conditions for Lz activation utilized
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an equimolar ratio of primary amine groups relative to activating reagent and
introduced 2 to 2.5 thiol groups per Lz. Similar reaction parameters were screened to
optimize the activation of Tf with its thiol reactive group. Tf was optimally activated at
pH 7.0, 25 oC using 50 M of Tf and a ratio of Tf to activating reagent of 1:2 for 90 min.
Under these conditions, the average number of functional groups incorporated into Tf
was 1.5. In the final round of optimization, formation of the Lz‐Tf conjugate was
monitored as a function of pH, time, temperature as well as the extent of activation of
each protein. The highest yield of a 1:1 Lz‐Tf conjugate was obtained at pH 7 allowing
optimally activated Tf and Lz (50 M each) to react for 12 h at 4 oC Nevertheless, even
though ESI MS analysis of the optimized conjugation reaction (Figure 2.4A) clearly shows
the presence of the 1:1 Lz‐Tf conjugate (charge states assigned based on the calculated
mass of 94.4 kDa are shown in Figure 2.4A with dotted lines), a large number of other
species are also present in the mixture. Therefore, evaluation of various properties of
Lz‐Tf is impossible without its separation from other products and/or reagents. Since the
incremental mass increase of Lz‐Tf over intact Tf makes use of SEC impractical for
purification of the conjugation products, alternative methods of separating the 1:1 Lz‐Tf
conjugate from other components of the reaction mixture were examined.
The significant difference in pI values for Tf (5.5‐6.3) and Lz (11.0) made ion
exchange chromatography (IXC) particularly attractive as a means of purifying the
reaction products. Using a weak cation exchange stationary phase, a mobile phase
buffered to pH 6.5, and a shallow salt gradient we have been able to achieve separation
between the Tf and Lz peaks exceeding 15 minutes (Figure 2.4C), with Lz homo‐
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polymers having even longer elution times. The products of the Lz/Tf conjugation
reaction elute within a wide (9‐17 min) time period and are mostly unresolved, although
a distinct peak is observed at 14 min elution time. Collection of a corresponding IXC
fraction (13.5‐14.5 min) followed by quick desalting and off‐line ESI MS analysis yields a
mass spectrum consistent with the 1:1 Lz‐Tf conjugate as the major component of this
fraction (Figure 2.4B).
Even though the collected IXC fraction represents a 1:1 Lz‐Tf conjugate, there still
might be a significant degree of micro‐heterogeneity due to the presence of modified
Lys side chains on the surfaces of both Tf and Lz. Indeed, native ESI MS analysis of this
fraction spiked with intact Tf (Figure 2.5) clearly shows significantly broader peak shapes
for multiply charged Lz‐Tf ions compared to intact Tf ions. A more detailed analysis of
the mass spectrum reveals very convoluted peak shapes for Lz‐Tf ions (insets in Figure
2.5), where the broad mass distribution of ionic species is due to the presence of either
unreacted maleimide groups on the surface of Tf and/or dead‐end NSI groups on the
surface of Lz. Despite these extensive modifications, no large scale conformational
changes are apparent as a result of the conjugation reaction, as the charge state
distribution of Lz‐Tf ions is consistent with both components of the conjugate
maintaining compact structures in solution (no ions were detected in the low m/z
region, whose presence in ESI MS usually signals either partial or complete protein
unfolding in solution117).
2.3.2. Influence of conjugation and chemical modifications on interaction with
transferrin receptor (TfR)
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Although examination of the Lz‐Tf conjugate with native ESI MS suggests that
neither protein undergoes unfolding as a result of the conjugation, the ability of both Tf
and Lz to interact with their physiological partners and/or therapeutic targets may
nonetheless be compromised as a result of unfavorable location of the cross‐link, as well
as multiple modification of Lys residues on the surface of either protein beyond the
cross‐link sites. For example, Lz cross‐linked to Tf may interfere with the ability of the
latter to bind to TfR, thereby rendering Lz‐Tf incapable of crossing the BBB.
Native ESI MS provides an easy way to evaluate protein binding to a variety of
ligands, including both small molecules and biopolymers,118, 119 and in some instances
allows the binding affinity to be estimated.120, 121 This approach has been used in the
past to monitor TfR recognition by wild type Tf and its mutants under a variety of
conditions,122,

123

and recently we were successful in using this approach to monitor

interactions of a Tf‐based fusion protein with TfR.124 However, native ESI MS has never
been used to evaluate interaction of protein‐protein conjugates with their physiological
partners. An ESI mass spectrum of the Lz‐Tf/TfR mixture acquired in this work under
near native conditions (neutral pH, ionic strength 20 mM) clearly indicates that the
receptor does recognize the conjugate, although the binding affinity is diminished
compared to intact Tf (Figure 2.6). Indeed, no ionic signal of unbound Fe2Tf is detected
in the mass spectrum of the Fe2Tf/TfR mixture, consistent with the receptor‐binding
affinity of Fe2Tf being in the sub‐µM range (concentration of both proteins in the
Fe2Tf/TfR mixture was in the low‐µM range, 3 µM). At the same time, the presence of a
weak, but detectable ionic signal of unbound Lz‐Tf in the mass spectrum of the Lz‐Tf/TfR
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mixture acquired under identical conditions suggests that the TfR binding affinity of the
conjugate is in the low‐µM range. This affinity range is close to that of intact apo‐Tf,123
even though the conjugate was saturated with iron following its isolation from the
reaction mixture and its measured mass is in agreement with the diferric form.
Nevertheless, even this lower receptor affinity should be sufficient for transient binding
to TfR at the cell surface (endogenous Tf is only 30% saturated with iron), and may
actually prove beneficial for dissociation from TfR upon crossing the BBB.
2.3.3. Influence of conjugation and chemical modification on enzymatic activity
In order to exhibit bacteriostatic properties, enzymatic activity of Lz must be
preserved within the conjugate. Enzymatic activity of Lz and its variants is frequently
probed using the short tri‐saccharide NAG3 as a surrogate substrate to demonstrate the
substrate‐binding competence of the protein125 (Figure 2.7A). Despite the proximity of
the six Lys residues (targets of modification by Traut’s reagent) to the catalytic site of
the enzyme, Lz‐Tf retains the ability to bind NAG3, indicated by the presence of the
protein‐NAG3 complexes in the mass spectrum of a Lz‐Tf/NAG3 mixture (Figure 2.7B)
acquired under near‐native conditions (neutral pH and 20 mM ionic strength), a
behavior very similar to that exhibited by intact Lz.
Despite the promising substrate binding results obtained using NAG3, a photometric‐
based activity assay that measures the lysis of Gram‐positive bacteria126 indicated a very
significant loss of bacteriolytic activity by Lz‐Tf (Figure 2.8). As can be seen in Table 2.1,
the bacteriolytic activity of Lz‐Tf is reduced by two orders of magnitude compared to the
control (intact) Lz, which may be attributed to two factors. First, chemical modification
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of Lys residues on the Lz surface changes the electrostatic properties of this protein (as
reflected by its behavior in IXC, vide supra), which may introduce conformational
changes in the vicinity of the catalytic site, thereby adversely affecting the ability of this
enzyme to recognize large substrates. Second, the presence of a large protein (Tf)
anchored to a Lys chain located in the vicinity of the catalytic site of Lz may introduce
steric effects, which would make it more difficult for this protein to attack the bacterial
cell wall even in the absence of any conformational changes.
Importantly, bacteriolytic activity of the Lz dimer is reduced four‐fold, the actual
activity of the dimer is 37.2 % compared to that of intact Lz, and is reported as 18.6 % in
Table 2.1 after adjusting it by a factor of 2 due to the presence of two catalytic sites in a
single Lz2 molecule. The Lz dimer byproduct conveniently serves as an important control
demonstrating that while chemical modification of primary amines on the enzyme
surface by Traut’s reagent contributes to the reduction in catalytic activity, it is not the
primary reason for Lz inactivation (this is also consistent with the observed ability of Lz‐
Tf to bind short substrate surrogates, vide supra). Therefore, the impaired ability of Lz‐Tf
to catalyze the hydrolysis of large glycans is largely due to the significant steric restraints
introduced by a bulky “anchor” (Tf). Metaphorically, Tf can be viewed as an “elephant
on a leash,” which allows the payload to be delivered to a desired location by
overcoming physiological barriers, but also restricts its freedom, thereby making it less
effective in exerting the desired therapeutic action.
One possibility to mitigate this negative effect is offered by longer linkers, which
should increase the freedom of movement of Lz cross‐linked to Tf, allowing it to attack
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the bacterial cell walls more effectively. A possibility to create protein/protein conjugate
with a longer linker is offered by amine‐reactive SM(PEG)12, which also introduces a
thiol‐reactive maleimide group on the protein surface (Figure 2.2C). Activation of Tf with
this reagent and introduction of free thiol groups to Lz using, SATA (to avoid formation
of dead‐ended by‐products introduced by the Traut’s reagent, see Figure 2.3 B and D)
leads to formation of a conjugate that is recognized by TfR (see Supporting Information
Figure S2) and has anti‐bacterial activity over an order of magnitude higher than that of
the conjugate with a short linker (Figure 2.8). Although a fraction of that increase could
be attributed to using SATA as the enzyme‐modifying reagent (note that the covalent
dimer of SATA‐modified Lz retains half the activity of the intact enzyme, see Table 2.1),
the most significant gain is a result of using the longer (and more flexible) linker.
2.4.

Discussion

The incidence of CNS infections (brain infections) is rising at an alarming rate, while
the treatment options remain very limited.104 Only a very small faction of existing small‐
molecule medicines can penetrate the BBB, and none of the currently approved protein
therapeutics is capable of doing so. Coupled with the ever increasing resistance of
pathogens to common antibiotics and dire side effects of the immune system’s
inflammation response to infection (frequently leading to brain abscess), this presents
the clinicians with a grave challenge. Clearly, there exists a significant and unmet need
for novel (bio)pharmaceuticals that can control CNS infections in the most efficient way
without eliciting an immune response from the host.
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Chemical conjugation of a therapeutic payload (a small molecule medicine or a
protein drug) to a transport protein, such as Tf, offers a convenient and inexpensive way
to produce effective medicines that can be delivered to target tissues and cells.
However, only one Tf‐based therapeutic has ever reached Phase III clinical trials and was
subsequently withdrawn.127, 128 This rather modest record of success can be explained
by the tremendous complexity and heterogeneity of conjugate species, a feature that
not only complicates the underlying biology, but also frequently prevents effective
utilization of state‐of‐the‐art analytical technologies at various stages of the drug
development process. MS has been a critical component in the analytical
armamentarium supporting protein drug development efforts,129, 130 but its applications
in characterization of protein‐protein conjugates, such as TransMID, have been very
limited so far. Lower‐end analytical techniques, such as size‐exclusion chromatography
(SEC) and circular dichroism (CD) spectroscopy, which have been traditionally applied to
characterize protein‐protein conjugates,131 do not provide sufficient resolution and may
in fact be misleading when relied upon as a sole source of information to describe the
conjugate’s molecular weight distribution or its conformation.
In this work we demonstrated that ESI MS can provide characterization of both the
products and intermediates of protein‐protein conjugation reactions at great detail.
Characterization of the activated proteins with ESI MS provides an important feedback
for optimization of the conjugation protocol, while MS analysis of the reaction products
highlights the enormous degree of structural heterogeneity and underscores the need
for chromatographic separation as a means of controlling the extent of heterogeneity.
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MS characterization of the IXC‐purified 1:1 conjugation product demonstrates that its
heterogeneity is substantially reduced, but not completely eliminated, as the mass
distribution reveals a significant number of additional chemical modifications to both
protein components of the conjugate. Another level of structural heterogeneity is due
to the large number of combinations that can be used to describe the spatial
distribution of both the cross‐link and unreacted modification sites on the surface of
each protein component. Although structural heterogeneity at this level is not apparent
when considering MS data alone, it can be easily visualized when methods of tandem
mass spectrometry (MS/MS) are applied either in conjunction with enzymatic
degradation of the conjugated protein, or alone (the so‐called top‐down MS/MS), an
approach that has been used successfully in the recent past to characterize the
distribution of conjugation sites in PEGylated proteins132 and protein‐small molecule
drug conjugates.133 Since it is likely that the location of the linker influences the activity
of the conjugate, identifying specific conjugation sites utilizing mass spectrometry will
be the focus of future work. Ideally, one would be able to correlate linker position with
conjugate activity allowing for yet an additional level of optimization in the design of the
protein conjugate.
Structural complexity and heterogeneity of the Lz‐Tf conjugate highlighted by ESI MS
brings to the fore the question of how conjugation and chemical modification may affect
the ability of Tf to be recognized by its receptor, a crucial first step in receptor‐mediated
transcytosis, without which no delivery of the payload to CNS would be possible. ESI MS
has been used in the past to monitor protein‐receptor interactions involving protein
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drugs, such as association of interferon β1a (AvonexTM) with its cognate receptors, and
to evaluate the modulation of its receptor‐binding competence by a specific (well‐
defined) chemical modification.134 Heterogeneity of the 1:1 conjugation product of Lz
and Tf does not allow a precise correlation between structural changes and receptor‐
binding properties to be established. Instead, TfR‐binding competence is evaluated in
this work for the entire ensemble of Lz‐Tf species. Although native ESI MS analysis
provides evidence for some loss of the receptor affinity, the conjugate is nonetheless
clearly recognized by the receptor. The ability of Lz‐Tf to associate with TfR suggests that
transfer of this species from the bloodstream to the CNS via receptor‐mediated
transcytosis is possible (and likely), although the efficiency of this process can be
estimated only by in vivo studies capable of measuring protein levels in various
biological fluids (a direction actively pursued in our laboratory135).
ESI MS also provides an exciting opportunity to evaluate the retention of enzymatic
activity of Lz following its conjugation to Tf. Since the therapeutic targets of Lz
(peptidoglycans from the cell walls of Gram‐positive bacteria) are too large and
heterogeneous for direct ESI MS analysis, most studies use a trisaccharide molecule
NAG3 as a surrogate substrate. Interestingly, native ESI MS measurements indicate
robust binding of NAG3 to Lz‐Tf, while the actual biological activity test indicates a
significant (by over two orders of magnitude) loss of its bacteriolytic activity compared
to intact Lz. Auto‐conjugation of Lz does not result in such a dramatic loss of
bacteriolytic activity of this protein, suggesting that it is the presence of a large anchor
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(Tf), rather than the chemical modification of the enzyme surface, that prevents Lz‐Tf
from effective execution of its desired therapeutic function.
An obvious solution to a steric hindrance problem is introduction of a longer and/or
more flexible linker between the payload and the transport protein. Switching from
SMCC (spacer arm length 8.3 Å) to SM(PEG)12 (53.4 Å) results in a dramatic increase of
autonomy for each protein component within the conjugate product, leading to a nearly
30‐fold increase of its bacteriostatic activity. Such a dramatic recovery of the
antibacterial activity of the conjugate is well beyond the much more modest
enhancement provided by switching from the Traut’s reagent to SATA. In retrospect,
utilization of longer and more flexible linkers may seem an obvious measure to enhance
the potency of any conjugate by minimizing interaction of its two protein components;
however, this consideration is not always brought to the fore when a specific type of
conjugation chemistry is selected. In fact, it was the parallel analysis of ESI MS and
biological activity data that illuminated this problem in the Lz‐Tf conjugate and allowed
for rational optimization of the conjugate product, improving its therapeutic potential.
2.5.

Conclusions

A suite of ESI MS‐based methods has been applied to characterize the structural and
conformational integrity of a model bacteriostatic agent (Lz) conjugated to a transport
protein (Tf), as well as its interaction with a physiological partner (TfR) critically
important for delivery of this product to the CNS. Interaction of Lz‐Tf with therapeutic
targets was evaluated initially using ESI MS to monitor binding to a small surrogate
substrate (NAG3) followed by measuring its bacteriolytic activity, and comparing its level
34

to that of the intact Lz and Lz dimer. Analysis of these data led to the conclusion that
steric hindrance imposed by a large protein anchored closely to the Lz surface reduced
its biological activity. Increasing the autonomy of Lz by lengthening the linker lead to a
dramatic increase in the bacteriolytic activity of the conjugate. ESI MS has already
become an indispensable tool facilitating all stages of the protein drug development
process,129 and this work demonstrates the enormous potential of this technique as a
means to facilitate development of a range of therapeutically effective protein‐drug
conjugates. While mass spectrometry is beginning to enjoy wider acceptance in the
biopharmaceutical community beyond the trivial tasks of primary structure
elucidation,134, 136 its applications for the analysis of protein‐drug conjugates have been
limited primarily to measuring stoichiometry of the conjugation.137‐139 This field has
experienced an explosive growth in the past several years due to extensive efforts
invested in developing antibody‐drug conjugates (ADC),140, 141 and ESI MS clearly has a
tremendous potential in this arena by providing invaluable information beyond mass
measurement that can be used to optimize protein drug conjugate structures during
early stages of development, and further catalyzing the drug design efforts.
SUPPORTING INFORMATION
ESI mass spectra of intact Tf and Tf modified with the Traut’s reagent acquired under
denaturing conditions, and an ESI mass spectrum of the mixture of Lz‐Tf conjugate
(produced with SM(PEG)12 as a linker) and TfR acquired under near‐native conditions.
This material is available free of charge via the Internet at http://pubs.acs.org.
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TABLES
Table 2.1. Bacteriolytic activity of Lz‐Tf and related proteins
Samples

Rate (mAU/min)

Specific activity (%)

Blank (negative control)

0.0

0.0

Tf (20 µM)

0.0

0.0

Lz control (2.5 µM)

124

100

Lz‐Tf conjugate (6.7 µM)

1.5

0.45

Lz‐Tf conjugate (30.6 µM)

6.4

0.42

Lz‐Tf longer linker (6µM)

35

11.8

Lz dimer 2IT(7.5 µM)

138

18.6

Lz dimer SATA (2.5 µM)

125

50.6
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FIGURES

Figure S1. ESI mass spectra of intact Tf and Tf modified with the Traut’s reagent
acquired under denaturing conditions. The three traces correspond to an unmodified
Tf (blue), 1:10 (red) and 1:20 (purple) concentration ratio of Tf to Traut’s reagent in the
reaction. The higher charge state peaks of activated Tf compare to control Tf indicate
further unfolding due to the reduction of intramolecular disulfide bonds.
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Figure S2. ESI mass spectrum of the mixture of Lz‐Tf conjugate (produced with
SM(PEG)12 as a linker) and TfR acquired under near‐native conditions. BSA that was
present as an impurity in the TfR sample also served as a negative control to ensure
specificity of binding for the Lz‐Tf conjugate.
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Figure 2.2. Schematic diagrams illustrating conjugation of Tf to Lz using the Traut’s
reagent and SMCC (A) and SATA and SM(PEG)12 (B), and possible side reactions due to
excessive activation of the two proteins with the Traut’s reagent and SMCC (C).
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Figure 2.3. ESI mass spectra of activated Tf, charge state +32 (A) and Lz, charge state
+10 (B) showing a range of reactive groups attached to the surface of each protein. The
three traces shown in panel A correspond to a 1:2, 1:4 and 1:20 concentration ratio of
Tf to sulfo‐SMCC in the reaction. The two traces shown in panel B correspond to Lz
modified with Traut’s reagent for 12 hours on ice (the gray trace corresponds to the
protein‐to‐reagent molar ratio 1:2, the product kept at room temperature for 24 hours
prior to MS; and the black trace corresponds to the protein‐to‐reagent molar ratio 1:7,
MS analysis of the product was carried out immediately upon reaction completion).
The multiple peaks shown in panel B are due to the presence of both chemically active
(thiols) and de‐activated (rings) groups on the surface of Lz. All mass spectra were
acquired under denaturing condition (10µM total protein concentration in
water/methanol/acetic acid, 49:49:2 by volume). Panels (C) and (D) show Tf and Lz
activated with SM(PEG)12 and SATA, respectively. The series of peaks indicated with an
asterisk represent salt adducts.
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Figure 2.4. ESI mass spectra of crude (A) and IXC‐purified (B) conjugation products of
Lz and Tf. Panel C shows IXC chromatogram of the crude mixture (the fraction whose
mass spectrum is shown in panel B is highlighted in the chromatogram).
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Figure 2.5. ESI mass spectra of the purified 1:1 Lz‐Tf conjugate (short linker) spiked
with intact Tf (A) and a 1:1 conjugate produced with a longer linker (B) acquired under
near‐native conditions (3 µM of each protein in 20 mM ammonium acetate, pH 7.1).
Insets zoom in on a selected charge state for each of the conjugates.
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Figure 2.6. ESI mass spectra of Tf/TfR (A) and Lz‐Tf/TfR (B) mixtures acquired under
near‐native conditions (3 µM of each protein in 20mM ammonium acetate, pH 7.1).
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Figure 2.7. ESI mass spectra of NAG3/Lz (A), NAG3/Lz‐Tf (B), NAG3/Lz2 (C) and
NAG3/Lz‐Tf longer linker (D) mixtures acquired under near‐native conditions (5µM of
proteins and 10µM NAG3 in 20mM ammonium acetate, pH 7.1).
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Figure 2.8. Antibacterial activity data for Lz‐Tf conjugates compared to that of intact
Lz and Tf (A) and Lz dimers (B).
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CHAPTER 3
BIODISTRIBUTION STUDIES OF TRANSFERRIN‐BASED DRUG IN ANIMAL MODELS BY
INDUCTIVELY COUPLED PLASMA MASS SPECTROMETRY (ICP‐MS)

Son N. Nguyen, Hanwei Zhao, Cedric E. Bobst, Gokhan Elci and Igor A. Kaltashov
Department of Chemistry, University of Massachusetts Amherst, Amherst, MA
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3.1.

Introduction

Human serum transferrin (Tf) is a promising drug carrier with the ability to cross the
blood‐brain barrier that may enable specific targeting to cancer cells and non‐invasive
delivery of drugs to the central nervous system (CNS). In our previous work, lysozyme‐
transferrin conjugates (Lz‐Tf) were developed as a model CNS‐targeting drug. Lz‐Tf was
successfully synthesized and well characterized including in‐vitro studies,48 however, in‐
vivo quantitation proved challenging due to the very high background of endogenous Tf
(at least three orders of magnitude higher than injected Tf). Initially, a proteomics‐
inspired technique developed in our laboratory (based on

18

O‐labeling of cysteine

residues in the protein)142 was used to study the biodistribution of exogenous Tf in
animal models (rats). Despite the high sensitivity (0.2 ppm) of this method that enables
the quantitation of exogenous Tf in blood up to 24 hours following the injection, it was
not sufficient for studies of physiological barriers crossing (e.g., exogenous Tf could not
be detected in cerebrospinal fluid). Additionally, due to the high background level of
endogenous Tf, a Ni column was used to purify and preconcentrate the His‐tag
containing recombinant form of Tf from the biological samples post‐administration.
However, since recombinant therapeutic proteins have their His‐tags removed prior to
administration, reliance on the His‐tag may limit the utility of this method. Thus, a very
high sensitivity universal method without reliance on a His‐tag for quantitation of
exogenous Tf and Tf‐based drugs in biological fluids and tissues is needed. Moreover,
multiplexing capable method that allows highly selective measurements of a reference
Tf alongside its variants and/or Tf‐drug conjugates to be carried out in a single animal
48

following injection is highly desired. This will not only significantly reduce the number of
animals needed for these studies but also results in a dramatic increase in the accuracy
of measurements.
In order to achieve this goal, our lab has recently developed a new sensitive and
selective method that uses metal tracers and inductively coupled plasma (ICP) MS with
the possibility of multiplexing for quantitation of exogenous Tf and Tf‐based drugs in
biological tissues and fluids. ICP MS is a very powerful technique for elemental
analysis,88‐90 especially for measuring metal‐ and metalloid‐containing compounds.91, 92
In the last several years, ICP‐MS has been applied to many different areas, particularly
bioanalysis93. Although Tf is a metalloprotein, its cognate metal ion (iron) is very
ubiquitous in all biological tissues and fluids and cannot be used as a tracer of Tf. In
order to solve this problem, Indium (In), a non‐endogenous metal that bind tightly to Tf
in form of a stable In2Tf complex were used as the metal tag.
Furthermore, metal tagged Tf and Tf‐based drugs also enable the biodistribution
study of proteins at tissue level by imaging LA‐ICP‐MS. Although imaging LA‐ICP‐MS for
the analysis of biological samples has been widely used in the last few years,94‐98 this is
the first time this imaging method was used for monitoring protein drugs with the help
of a metal tracer.
In this work, we apply this new sensitive and selective ICP‐MS based method for
quantitative profiling of exogenous Tf and Tf‐drug conjugate in biological fluids and their
corresponding distribution patterns in tissues.
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3.2.

Experimental

3.2.1. Preparation of indium (In) loaded Lz‐Tf conjugate
Lz‐Tf conjugate was synthesized as described previously.48 Lz from chicken egg white
(Sigma‐Aldrich, St. Louis, MO) was activated using N‐succinimidyl‐S‐acetylthioacetate
(SATA; Pierce Biotechnology, Rockford, IL), while human Tf (Sigma‐Aldrich, St. Louis,
MO)

was decorated with

thiol‐reactive maleimide

maleimidopropionamido]‐dodeca‐ethyleneglycol)

ester

groups (succinimidyl‐([N‐
(SM(PEG)12;

Pierce

Biotechnology, Rockford, IL). The 1:1 Lz‐Tf conjugate was isolated by cation exchange
chromatography on a 4.6 x 100 mm PolyCATA™ column (5 µM, 1000 Å, PolyLC Inc.,
Columbia, MD) using an Agilent 1100 (Agilent Technologies, Palo Alto, CA) HPLC system.
Indium (In) was then loaded to Lz‐Tf following the removal of iron as described
previously.143
3.2.2. Animal Models
Experiments were carried at the animal facilities of the University of Massachusetts,
Amherst on 10‐week‐old, male Wistar rats purchased from Charles River Laboratories
(Wilmington, MA, USA). Rats were housed in controlled light (12 h light/dark cycle),
temperature and humidity conditions with free access to food and water. All animal
experiments were complied with the National Institute of Health Guidelines for Animal
Care and were approved by the University of Massachusetts, Amherst Institutional
Animal Care and Use Committee.
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Animals were divided into three groups: G1: control rats (i.v. injected with 100 mM
sterilized PBS solution); G2: Tf rats (i.v. injected with 5mg/kg dose of In2Tf); G3: Tf‐Lz rats
(i.v. injected with 5mg/kg dose of In2Tf‐Lz). All In2Tf and In2Tf‐Lz samples were buffer
exchanged into 100mM sterilized PBS buffer solution prior to injections. Rats were
euthanized by CO2 overdose 24 h after injection. Blood samples were collected in
heparin coated tube to prevent coagulation. Organs of interest (liver, spleen, lungs,
kidneys, heart, intestine and brain) were harvested, rinsed in PBS, dried, weighed and
stored in a ‐80oC freezer. The experimental sequence is presented in Figure 3.1.
3.2.3. ICP‐MS
Small pieces cut organs (50mg) were oxidized in 0.5 mL of acid mixture (67% HNO3
and 30% H2O2 at a 3:1 volume ratio) and shaken overnight at 50oC until they dissolved
fully. After the addition of 1ppb Rh as internal standard and 9.5 mL of deionized water,
the sample was centrifuged at 3200 × g for 15 min to remove cell debris, leaving the
supernatant for Indium content analysis using a NexION 300X ICP‐MS (Perkin Elmer,
Waltham, MA, USA). Prior to the analysis, daily tuning was done to make sure the
instrument was in optimum conditions. All signals were obtained using the collision cell
with kinetic energy discrimination mode (KED). Operating conditions for the experiment
are illustrated in Table 3.1. A calibration curve of various signal ratio of In/Rh was used
to measure the In content, using 2.5% HNO3 and 0.37% H2O2 as the blank. All data were
reported as In concentration in ppb (ng/g) and Tf concentration in ppm (µg/g) as well as
the injected dose percentages. Error bars indicate 1SD from three different rats in each
group.
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3.2.4. Imaging LA‐ICP‐MS
Organs of rats were embedded in Tissue‐Tek® O.C.T. compound (Sakura Finetek
USA, Torrance, CA, USA) and cryocut at ‐20oC into slices of 20 µm thickness with a LEICA
CM1850 cryostat (Leica Microsystems GmbH, Wetzlar, Germany). The slices were placed
on regular glass slides and air dried. Experiments were conducted with a CETAC LSX‐213
G2 laser ablation system (Nebraska, USA) coupled to the Perkin Elmer NexION 300X ICP‐
MS. LA unit was synchronized with the ICP‐MS in external triggering mode. Organs
sections were inserted into the cell and ablated line by line. The operation conditions for
laser ablation system are listed in Table 3.1. Elemental images were reconstructed using
ImageJ, an open source image generator software (http://rsbweb.nih.gov/ij/), following
the extraction and compilation of individual element list of pixels from raw data files,
each of which was acquired from a single ablated line contains values for all three metal
measured.
3.3.

Results and discussion

3.3.1. In Vivo Distribution of Tf and Lz‐Tf
The ICP‐MS based method for transferrin‐based therapeutics quantitation using 115In
as a metal tracer recently developed in our lab was used in this work for in‐vivo tracking
of the injection of In2Tf and In2Lz‐Tf by quantitating their localization to key organs.
Exogenous Tf and Tf‐Lz concentration from spleen, liver, kidney, lung, heart, intestine
and brain as well as body fluids i.e. blood, urine and CSF collected 24 hours post‐
injection was determined by measuring

115

In concentration. Despite the complexity of
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the sample matrix as well as the presence of large number of impurities, largely from
inexpensive H2O2 and HNO3 used for sample digestion prior to analysis, two stable
isotopes of In (113In and

115

In) could be readily resolved by ICP‐MS. The distribution of

the In2Tf and In2Lz‐Tf in organs and body fluids 24 hours after intravenous injection is
shown in Figure 3.1. Panel A shows absolute In concentration from 3 groups directly
measured from organs, while panel B indicates the In contents as a fraction of the
injected dose. Data from control group indicates that the sources of error were mainly
from chemical impurities and instrumental noises other than that of method and human
error. At the organ level, spleen (15.2±3.2µg/g), liver (14.1±3.5µg/g), kidney (14.4±3.6
µg/g) and intestine (4.6±1.6 µg/g), as expected, are the highest uptake organs given the
fact that they all play a very important role in clearance of blood‐circulating drugs.
Spleen is the body’s largest filter of the blood in which old erythrocytes are removed
and iron is recycled.144 On the other hand, liver is the largest internal organ in which
chemicals and metabolized drugs are detoxified and filtered blood coming from the
digestive tract is passed to the rest of the body.145 Contrary to that, a relatively low level
of In accumulation is observed in organs that do not play a role in drugs clearance such
as the heart (2.1±0.4µg/g) and lungs (3.4±0.4µg/g). Additionally, there was a noticeable
abundance of In2Tf in the blood circulation (4.7±1.9µg/g). However, when the size of
organs taken into consideration, 115In was largely accumulated in liver and blood (~30%
injected dose) and to a lesser extent, kidney (~9%), intestine (~9%), spleen (~3%), lung
(~1%) and heart (~1%) (figure 3.2 B). The fairly low In2Tf contents in the brain
(220±11ng/g) and CSF (92±28ng/g) may be attributed to the fact that human Tf was
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used in all experiments instead of rat Tf. Importantly, with the high sensitivity of the
method, In can still be detected in the CSF of dosed rats. However, a better quantitation
limit (LOQ) is still needed in order to confidently quantitate human Tf in rat CSF and to
facilitate in‐vivo studies of physiological barrier crossing and determine the physiological
fate of an injected Lz‐Tf conjugate. The reported ICP‐MS instrumental detection limit of
In is at sub‐ppt levels, which equates to sub‐ppb levels of Tf. Theoretically this
represents a substantial improvement over the currently used procedure based on 18O
labeling that relies upon a His‐tag containing recombinant form of Tf. Our method LOQ
for In, however, currently reaches the sub‐ppb level but efforts to further improve this
are underway.
3.3.2. Distribution of Lz‐Tf at tissue level by imaging LA‐ICP‐MS.
As a powerful imaging technique, LA‐ICP‐MS has recently been used to produce
distribution images of elements in thin human or rodent tissue sections.146 In order to
assess distribution of In2Lz‐Tf in organs of interest we attempted to apply this technique
for mapping the In2Lz‐Tf at the tissue level. In this work, organs were cryosected into
thin layers of 50 µM thickness and mounted on glass slides. LA‐ICP‐MS was operated in
line scanning ablation mode (line by line) with all the optimized experimental
parameters provided in Table 3.1. The quadrupole mass filter was set to simultaneously
measured signals from

115

In,

57

Fe and

63

Cu (iron and copper are two ubiquitous

endogenous metals).
The metal distribution images in the spleen and brain section are shown in Figure
3.3 and Figure 3.4. Panel A in both figures show the micro‐photographs of the ablated
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slices illustrating the location of histological features in the samples. Panels B, C and D
show the distribution images of 57Fe, 63Cu and 115In respectively. Although the resolution
achieved (100µm x 7µm pixel) was adequate for the differentiation of the distribution of
elements in specific histological areas, it could still be improved more by reducing spot
size and scan speed. As expected, there were some similarities between the distribution
of Fe and In whereas Cu shows a more homogenous distributed.
In spleen, a clear accumulation of Fe and In in the red pulp could be observed
(Figure 3.4 B and D). An explanation for this observation may be the fact that red pulp
area is where all the blood filtration units, the sinusoids are located. Blood cells as well
as bloodstream clutter particles, i.e. nuclear remnants, platelets, and denatured
hemoglobin are mechanically filtered here as they enter the spleen.147 It is worth noting
that red pulp also functions as the red blood cell reservoir. The high blood circulation in
this region explains the high abundance of Fe and In as they are components of plasma
proteins. On the other hand, the white pulp which closely resembles the structure of a
lymph node and where antibodies are synthesized is organized with T‐ and B‐cell
compartments. Here, antibody‐coated bacteria and antibody‐coated blood cells are
removed via blood and lymph node circulation.144 That explains the low abundance of
Fe and In in these areas.
Similar to what was observed from homogenized brain measurements, the low
abundance of In showed in LA‐ICP‐MS images from dosed rats’ brain (figure 3.4) was
most likely due to the use of human Tf in all experiments instead of rat Tf. Despite this
caveat, the signal from In was still distinguished from the tissue background in
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reconstructed image which shows similar histological features to the photograph of
brain section. Based on the data acquired from the measurements of homogenized thin
brain cross‐sections, In content was calculated to have an average of 5x10‐15g per
ablated pixel (700µm2) assuming it is homogenously distributed. This example not only
demonstrates the outstanding capabilities of LA‐ICP‐MS for mapping metal coded
protein drugs at cellular level (less than 100µm) but also provides us with a powerful
tool to monitor the successful delivery of cancer‐targeting Tf conjugates to animal
cancer models.
3.4.

Conclusions

Although attempts to study the biodistribution of exogenous Tf and Tf‐based
therapeutics in animal models (rats) using a proteomics‐inspired 18O‐labeling technique
made the detection of Tf in blood possible, it was not sufficient for studies of
physiological barriers crossing (e.g., exogenous Tf could not be detected in cerebrospinal
fluid). A new sensitive and selective ICP‐MS based method using non‐cognate metal
tracers was applied for the quantitation of exogenous Tf and Tf‐based drugs in biological
tissues and fluids. Our in‐vivo studies tracked the injection of In2Tf and In2Tf‐Lz by
quantitating its localization to key organs. We found that Lz‐Tf had accumulated largely
in spleen (15.2±3.2 µg/g), liver (14.1±3.5µg/g), kidney (14.4±3.7µg/g), intestine (4.6±1.6
µg/g) and blood (4.7±1.9µg/g), and to a lesser extent in the lungs (3.4±0.4µg/g), heart
(2.1±0.4µg/g) and brain (220±11ng/g). Although the used of human Tf in all experiments
instead of rat Tf may have resulted in low Lz‐Tf contents in CSF (92±28ng/g), it can still
be detected thanks to the high sensitivity of the method. However, better quantitation
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limit (LOQ) is still needed. LA ICP‐MS in cryosections of organs of interest was also
assessed. We have demonstrated the imaging capabilities of LA‐ICP‐MS for studying
biodistribution of metal coded protein drugs at cellular level. This is also a promising
tool for the tracking of cancer‐targeting Tf conjugates delivery to tumor cells.
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TABLES
Table 3.1. Operating parameters of LA‐ICP‐MS
ICP‐MS parameters

Laser Ablation parameters

Nebulizer Gas Flow

0.9‐1 L/min

Spot Size

100 µm

Auxiliary Gas Flow

1.4 L/min

Scan rate

20 µm/sec

Plasma Gas Flow

16.5 L/min

Laser energy

3.34 J

ICP RF power

1600 W

Frequency

10 Hz

Analog Stage Voltage

‐1600 V

Shutter delay

10 sec

Pulse Stage Voltage

950 V

Gas flow rate

600 mL/min

Deflector Voltage

‐12 V

Space between lines

0 µm (no space)

Dwell time

50 ms
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FIGURES

Figure 3.2. Schematic of the ICP‐MS based method for tracking Tf‐based therapeutics
distribution in organs and fluids.
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Figure 3.3. Organ distribution of 115In over a 24 hours period after intravenous
injection (A). Indium contents of some key organs are normalized to % injected dose
(B). Each result represents the mean ± 1 SD from three rats.
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Figure 3.4. LA‐ICP‐MS images for the simultaneous monitoring of 57Fe, 63Cu, and 115In
on spleen sections from rats treated with a single dose of In2Lz‐Tf. Optical image of
parallel sections for comparison purposes.
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Figure 3.5. LA‐ICP‐MS images for the simultaneous monitoring of 57Fe, 63Cu, and 115In
on brain sections from rats treated with a single dose of In2Lz‐Tf. Optical image of
parallel sections for comparison purposes.
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CHAPTER 4
STUDY OF IN‐VIVO AGGREGATION OF TRANSFERRIN‐BASED DRUG BY SIZE EXCLUSION
CHROMATOGRAPHY AND INDUCTIVELY COUPLED PLASMA MASS SPECTROMETRY

Son N. Nguyen and Igor A. Kaltashov
Department of Chemistry, University of Massachusetts Amherst, Amherst, MA

4.1.

Introduction

Previously, lysozyme‐transferrin conjugates (Tf‐Lz) were developed as a model CNS‐
targeting drug. Tf‐Lz was successfully synthesized and well characterized including
stability testing.48 In‐vitro studies have indicated that although the Tf‐Lz conjugate was
produced as a monomer, it has the propensity to aggregate. Protein aggregation is a
process that impairs protein activity both directly and indirectly (e.g., by reducing
solubility).148 This phenomenon is of serious concern for protein drugs not just because
it economically affects the production process but it also raises safety issues.149
However, all studies to date have been only done in‐vitro. It is obviously a serious
concern that Lz‐Tf conjugates might aggregate even more when injected into live
animal. Thus, it is important to study the aggregation of Tf‐based drugs in‐vivo in order
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to assess this propensity. However worth noting that, with the existing tools, it is
extremely challenging to track the aggregation process in‐vitro, let alone in‐vivo study.
The most commonly used methods for the detection of soluble protein aggregates
include size exclusion chromatography (SEC),150 Capillary Electrophoresis (CE), analytical
ultracentrifugation (AUC),151 light scattering techniques (MALLS, DLS),152 field flow
fractionation (FFF)151 and electrospray ionization mass spectrometry (ESI‐MS).153 Among
those techniques, SEC is undoubtedly the most widely used for characterization of
aggregate size and content thanks to its ease of use, low cost, and high throughput.150
However, none of the aforementioned methods have the ability to detect protein
aggregation in‐vivo due to the complexity and high abundance of background proteins.
In order to achieve this goal, our lab has developed a new method that uses metal
tracers and inductively coupled plasma (ICP) MS with the help of SEC for in‐vivo
quantitation of Tf‐based drugs aggregation post injection. This method relies on SEC to
separate different forms of In2Tf‐Lz conjugates (oligomers (aggregates) or monomers)
and uses ICP‐MS to quantitate the concentration of each form via the In concentration.
ICP MS is a very powerful technique for elemental analysis,88‐90 especially for measuring
metal‐ and metalloid‐containing compounds.91, 92 In the last several years, ICP‐MS has
been applied to many different areas, particularly bioanalysis93. Additionally, ICP‐MS‐
based methods are not affected by the abundance background proteins of biological
samples (i.e. body fluids) thanks to their high degree of selectivity toward metals, thus,
no purification and preconcentration steps are required. Our previous studies have
proved that Indium (In), a non‐endogenous metal can be used as the Tf‐based drugs
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metal tracer since it binds tightly to Tf forming a stable In2Tf complex. It is clear that this
ICP MS based method using metal tracers enables protein quantitation, however, it
does not provide any information about protein aggregation. Fortunately, it can be used
as a very powerful protein detector for separation techniques that are capable of
characterizing protein aggregation such as SEC and CE. In this work, we use the
combination of SEC and ICP‐MS for in‐vivo quantitation of Tf‐based drugs aggregation
post injection.
4.2.

Materials and methods

4.2.1. Preparation of indium (In) loaded Lz‐Tf conjugate
Tf‐Lz conjugate was synthesized using the protocol that was described previously.48
Indium (In) was then loaded to Tf‐Lz following the removal of iron as also described
previously.143
4.2.2. Animal Models
Experiments were carried at the animal facilities of the University of Massachusetts,
Amherst on 10‐week‐old, male Wistar rats purchased from Charles River Laboratories
(Wilmington, MA, USA). Rats were housed in controlled light (12 h light/dark cycle),
temperature and humidity conditions with free access to food and water. All animal
experiments complied with the National Institute of Health Guidelines for Animal Care
and were approved by the University of Massachusetts, Amherst Institutional Animal
Care and Use Committee.
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Animals were divided into two groups: G1: control rats (i.v. injected with 100mM
sterilized PBS solution); G2: Tf‐Lz rats (i.v. injected with 5mg/kg dose of In2Tf‐Lz). All
In2Tf‐Lz samples were buffer exchanged into 100mM sterilized PBS buffer solution prior
to injections. Rats were euthanized by CO2 overdose 24 h after injection. Blood samples
were obtained in heparin coated tube to prevent coagulation and divided into aliquots
of 200µL each, stored in the ‐80oC freezer. Rat plasma was prepared by centrifuging
blood from control rats immediately after collection for a minimum of 10 minutes at
1000‐2000 RCF (generally 1300 RCF) at room temperature. Supernatant (plasma) was
then carefully aspirated, aliquoted into vials (200µL) and stored at ‐80oC. The
experimental sequence is presented in Figure 4.1. Storage conditions experiments are
shown in the bold black boxes; in‐vitro, ex‐vivo and in‐vivo studies showed in bold red,
blue and green boxes respectively.
4.2.3. Instrumentation.
An Agilent 1100 series liquid chromatography (Agilent Technologies, Santa Clara, CA)
equipped with a TSK Gel 3000 SWXL column (TOSOH Bioscience, King of Prussia, PA) was
used for SEC analysis. The separation was performed with 150 mM ammonium acetate
(pH 7.0) at a flow rate of 0.8 mL/min and was monitored with 280 nm UV detection. The
injected sample volume was 20 μL for storage condition tests (5µM Lz‐Tf sample) and
10µL for all other samples.
All ESI MS measurements were carried out with a QStar‐XL (ABI/SCIEX, Toronto,
Canada) hybrid quadrupole/time‐of‐flight MS equipped with a nanospray source. The
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position of the ESI emitter and spray voltage were carefully adjusted to optimize the
spray efficiency, which directly affected the resolution of the mass spectra.
Three SEC fractions collected F1 (5.5 min ‐ 10.6 min), F2 (10.8 min – 13 min) and F3
(13.2 min – 17 min) were oxidized in 0.2 mL of acid mixture (67% HNO3 and 30% H2O2 at
a 3:1 volume ratio) and shaken for 1 hour at 50oC. After the addition of 1 ppb Rh as
internal standard, deionized water was added to bring the final volume to 5.0 mL.
Indium content was analysis using a NexION 300X ICP‐MS (Perkin Elmer, Waltham, MA,
USA). Prior to the analysis, daily tuning was done to make sure the instrument was in
optimum conditions. All signals were obtained using the collision cell with kinetic energy
discrimination mode (KED). Operating conditions for the experiment are illustrated in
Table 4.1. A calibration curve of various signal ratio of In/Rh was used to measure the In
content, using 2.5% HNO3 and 0.37% H2O2 as the blank. All ICP‐MS data were reported
as a fraction of total In. Error bars indicate 1 standard deviation from triplicate
measurements. Post‐acquisition analysis of both SEC and MS data was carried out using
Origin 8.0 (OriginLab Corporation, Northampton, MA) software.
4.3.

Results and discussion

4.3.1. Aggregation study of In2Tf‐Lz under typical storage conditions
In order to assess the stability (aggregation and degradation) of the Tf‐Lz conjugate
as a result of storage in typical conditions (e.g. in 4oC fridge or ‐20oC freezer), SEC, ESI‐
MS and ICP‐MS methods were applied. Freshly prepared In2Tf‐Lz conjugate was divided
into 50 µL aliquots of 5 µM protein concentration and stored either at 4oC or lyophilized
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and stored in a ‐20oC freezer. After one month, the stored samples were reconstituted
in 150 mM NH4Ac solution, pH 7.0 and analyzed by SEC, native ESI‐MS and ICP‐MS.
Figure 4.1 shows the experimental protocols for the test of Tf‐Lz conjugate stability.
Figure 4.2 shows data acquired from SEC and native ESI‐MS; Panel A indicates SEC
chromatograms of the freshly prepared samples along with 1 month stored samples
either at 4oC or ‐20oC. The early elution fraction (F1) corresponds to a high molecular
weight fraction being oligomers of Tf‐Lz i.e. aggregation. The second fraction (F2) shows
the Tf‐Lz monomer peak and lastly, F3 shows the small molecular weight fraction which
is where Tf‐Lz degradation products eluted; Panel B shows native ESI‐MS data of the
corresponding unfractionated samples. Degradation products of Tf‐Lz as well as
unfolded proteins and those with compromised (partially reduced or scrambled)
disulfide networks will appear at low m/z region (1000‐3000) while oligomers of Tf‐Lz
shows signals at high m/z region (above 5000). All samples had the same concentration
in the same 150 mM NH4Ac buffer, pH 7.0 for all SEC measurements and were diluted to
a final concentration of 1 µM in 150 mM NH4Ac, pH 7.0 for native Nanospray‐MS
analysis.
The SEC chromatogram of Tf‐Lz sample stored at ‐20oC shows that there was not
much change in the F1 region compared to that of freshly prepared Tf‐Lz. Sample stored
at 4oC, however, showed increasing of UV absorption in this fraction indicating
aggregation has occurred after 1 month in storage in the fridge and is ~ less than 5%
compared to the monomer peak shown in F2 region. Thus it appears that, almost no
hydrolysis products were observed in any of the samples indicating good stability of
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both proteins and chemical linkers. Native ESI‐MS data of the corresponding samples
are in good agreement with the SEC data. No noticeable Tf‐Lz degradation products
were found although low signal of Tf‐Lz oligomers were observed in all samples.
Furthermore, ICP‐MS measurements of In content of 3 collected fractions from SEC runs
indicate a low abundance of Tf‐Lz aggregation species (Figure 4.4). Interestingly, there
were noticeable In signals from F3 fraction of both freshly prepared Tf‐Lz conjugate and
the 1 month‐old sample indicating hydrolysis products. However, a closer look at the
results, indicated that those In signals were most likely coming from the tailing effect of
monomer peak in fraction F2 due to the high Tf‐Lz concentration used for these studies.
The good agreement among the three orthogonal methods namely SEC, native ESI‐MS
and ICP‐MS indicates that Tf‐Lz conjugate is stable under all typical storage conditions.
4.3.2. In‐vitro, Ex‐vivo and In Vivo aggregation study of In2Tf‐Lz
To further our understanding of the Tf‐Lz aggregation process, in‐vitro, ex‐vivo and
in‐vivo stability studies were performed using the method developed. For in‐vitro and
ex‐vivo studies, lyophilized In2Tf‐Lz sample was first reconstituted into 50 µL of 150 mM
NH4Ac, pH 7.0 to make roughly 5 µM solution of which 5 µL was either mixed with 45 µL
of 150 mM NH4Ac, pH 7.0 (in‐vitro) or 45µL rat plasma (ex‐vivo), followed by their 24h
incubation at 37oC. Each experiment was done in triplicate. The incubated samples
along with rat blood samples were then injected (10 µL) onto a SEC column and three
fractions were collected for each sample. Figure 4.3 illustrated SEC chromatograms of
In2Tf‐Lz kept under different conditions including freshly prepared (black trace, control
sample), 24h incubation in NH4Ac at 37oC (red trace, in‐vitro), 24h incubation in rat
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plasma at 37oC (blue trace, ex‐vivo) and blood of injected rats (green trace, in‐vivo). All
traces were normalized to their most abundant peaks. SEC data showed that the
aggregation and hydrolysis of Tf‐Lz conjugate after incubation in NH4Ac for 24h at 37oC
is not significant compare to that of fresh Tf‐Lz. Indeed, ICP‐MS measurement indicates
similar result (Figure 4.4).
As expected, SEC chromatograms of rat plasma and whole blood do not give us any
useful information due to the high abundance of background proteins. However, three
fractions were still collected based on their elution times as defined earlier (F1 (5.5min‐
10.6min), F2 (10.8min‐13min) and F3 (13.2min‐17min)). Figure 4.4 shows In content of
SEC fractions measured by ICP‐MS. Data were reported as fraction (percentage) of total
In concentration measured from all three collected SEC fractions. It is worth noting that,
ICP‐MS quantitation of total In concentration in blood circulation indicated that Tf‐Lz
conjugate concentration is 4.7±1.9µg/mL which is 10 times lower than in‐vitro studies.
Although background proteins are present at high abundance and blood samples were
diluted roughly 500 times due to the collecting process, In contents in all fractions were
confidently quantitated with high accuracy and precision. Importantly, the ICP‐MS
results of in‐vivo studies indicated that there were up to 15% In signal in F1 fraction.
Beside protein aggregation, there might be a possibility of conjugate bound antibody
and/or conjugate bound soluble Tf receptor (sTfR) in this fraction. This is still an
encouraging result since blood and plasma contain a number of proteases and other
enzymes as well as scavenger proteins that may affect and modify the structure of Tf‐Lz.
Even 24 hours post‐injection over 85% of Tf‐Lz conjugate was still in its monomeric
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form. Importantly, this ICP‐MS based method can be coupled as a detector online to
many separation and/or fractionation techniques such as capillary electrophoresis (CZE),
SEC or field flow fraction (FlFFF) to take full advantage of this powerful method of
characterizing the aggregation size, forms and make distinction of protein aggregation
from conjugate bound antibody and/or conjugate bound soluble Tf receptor (sTfR) as
well as achieving high throughput measurements. Others have attempted to study the
aggregation of biopharmaceuticals when mixed with human plasma using methods like
light microscopy, Fluorescence Single Particle Tracking (fSPT)154, light‐scattering (DLS)
and surface plasmon resonance (SPR)155. However, this is the first time in‐vivo
quantitation of a small soluble protein drug aggregation and degradation post‐injection
was studied.
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4.4.

Conclusions

Protein aggregation is a phenomenon that is a serious concern for protein drugs
regarding safety issues149 Traditional methods do not have the ability to detect protein
aggregation due to the complexity and high abundance of background proteins, even
with the help of purification and preconcentration.
This study has demonstrated that an ICP‐MS based method using metal tracer has
the ability to probe the protein stability post‐injection and yields useful data not
accessible by other methods. We found that, whilst the Tf‐Lz conjugate appears to be
stable under typical storage conditions as well as in the in‐vitro study i.e. it does not
show significant aggregation and degradation products, ex‐vivo and in‐vivo studies
indicate a noticeable aggregation formed. These results emphasize the importance of
analytical methods for in‐vivo quantitation of aggregation in biological fluids since
aggregation profile may drastically change post‐injection.
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TABLES
Table 4.1. Operating parameters of ICP‐MS
Nebulizer Gas Flow

0.9‐1 L/min

Auxiliary Gas Flow

1.4 L/min

Plasma Gas Flow

16.5 L/min

ICP RF power

1600 W

Analog Stage Voltage

‐1600 V

Pulse Stage Voltage

950 V

Deflector Voltage

‐12 V

Dwell time

50 ms
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FIGURES

Figure 4.1. Experimental scheme of the Tf‐Lz conjugate stability test
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A

B

Figure 4.2. SEC chromatograms and native ESI‐MS spectra of Tf‐Lz under storage
conditions; (A) SEC chromatograms of the freshly prepared samples along with 1
month stored samples either at 4oC or ‐20oC. The early elution fraction (F1)
corresponds to high molecular weight fraction being oligomers of Tf‐Lz i.e.
aggregation. The second fraction (F2) shows Tf‐Lz monomer peak and lastly, F3 shows
the small molecular weight fraction which is where Tf‐Lz degradation products eluted
out; (B) native ESI‐MS spectra of corresponding samples. Degradation products of Tf‐
Lz, if any, will appear at low m/z region (1000‐3000) while oligomers of Tf‐Lz shows
signals at high m/z region (above 5000). All samples had the same concentration in
the same buffer of 150mM NH4Ac, pH 7.0 for all SEC measurements and were diluted
to 1µM solution with 150mM NH4Ac, pH 7.0 for native Nanospray‐MS analysis.
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Figure 4.3. SEC chromatograms of In2Tf‐Lz in different conditions including freshly
prepared (black trace, control sample), 24h incubation in NH4Ac at 37oC (red trace,
in‐vitro), 24h incubation in rat plasma at 37oC (blue trace, ex‐vivo) and bloods of
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Figure 4.4. In contents of SEC collected fractions measured by ICP‐MS. Data were
reported as fraction (percentage) of total In concentration.
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CHAPTER 5
A NEW 18O LABELING METHOD FOR MODIFICATION SITES QUANTITATION OF
PROTEIN‐DRUGS CONJUGATES

Son N. Nguyen, Alex J. Johnson and Igor A. Kaltashov
Department of Chemistry, University of Massachusetts Amherst, Amherst, MA

5.1.

Introduction

Protein‐drug conjugates have emerged as a very promising approach for cancer
treatment.19 They combine the best features of both components, i.e. specificity of
carrier proteins and the potency of cytotoxic drugs. Usually, carrier proteins, such as
monoclonal antibodies (mAbs) or transferrin (Tf), are linked to cell‐killing drugs via
various chemical linkers which are crucial for the successful delivery. It is well known
that conjugation chemistry, particularly lysine‐based methods, introduces heterogeneity
and modifies the surface charges of the carrier proteins. In spite of recent advances,
characterization of intrinsic heterogeneity that may affect the pharmacokinetics, tissue
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distribution156 and the physicochemical stability of the conjugates157 still remains
challenging.
The site of conjugation is reported to have a significant impact on the stability (i.e.
aggregation, poor solubility and low stability in circulation) and bioactivity of the
conjugates.158 Ideally, the correlation of linker position to conjugate activity will allow
the optimization in design of the protein conjugate.159 It is worth noting that the
heterogeneity of conjugation sites is usually the most difficult to characterize.160 This
type of structural heterogeneity can be characterized using methods of tandem mass
spectrometry (MS/MS) with the help of enzymatic degradation of the conjugated
protein (peptide mapping) or top‐down MS/MS, a successful approach that have been
applied to characterize the distribution of conjugation sites in PEGylated proteins132 and
protein‐small molecule drug conjugates.133
Peptide mapping using chromatographic methods combined with MS analysis is a
universal tool for the detection and characterization of a wide variety of protein
modifications including PEGylation, oxidation, glycation, disulfide scrambling, and
crosslinking.161 More importantly, it can provide structural information about the
locations of conjugation sites. It is well known that trypsin cannot cleave at modified
lysines, hence, larger and more hydrophobic peptides are generated. Moreover,
modified peptides usually elute later than unmodified ones in reverse phase HPLC due
to the changes in surface charge and increase in hydrophobicity. Therefore, enzymatic
digests’ chromatograms of a protein drug conjugate are considerably different from
those of the unmodified protein thus helping identify specific modification sites of drug.
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Using this approach, modification sites of lysine‐modified maytansinoid‐monoclonal
antibody immunoconjugate, huN901‐DM1, were mapped using both trypsin and Asp‐N
as proteases.162 It is reported that all observed sites are partially modified and mostly
found in locations that are more exposed to solvent as well as those that have structural
flexibility.
Despite large number of studies published on this topic, most set out only to identify
the modification sites of protein drug conjugates, very few attempted to quantitate
them. However, quantitation of modification sites is commonly used in chemical
probing methods for characterization of protein structure, function, and ligand
binding.163,

164

In these studies, modified lysine sites were quantitated either using

extracted ion chromatogram (XIC) estimation165‐168 or iTRAQ (isobaric tags for relative
and absolute quantification) method.164 As an example, a chromogenic chemical probe
targeting lysines, termed “NN”, was used to study the surface accessibilities/reactivities
of lysozyme. Peak areas of all modified and unmodified peptides identified in the digests
from the XIC were used to calculate the reactivity of each lysine residue (epsilon‐amine)
and the N‐terminus.166 Although the XIC‐based method is a simple method, it suffers
from a fundamental error i.e. modified peptides have different ionization efficiencies
compared to unmodified ones. On the other hand, iTRAQ is a very powerful method
with multiplexing capability for relative and absolute quantitation of peptides and
proteins. However, iTRAQ quantitation requires commercial isobaric tags and is only
possible with tandem MS analysis, thus making it an expensive approach.
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Herein, we describe a simple and cost‐effective

18

O labeling‐based method for

quantitation of lysine modification sites of protein drug conjugates. The principle of this
method is based on the fact that trypsin cannot cleave at modified lysines, thus the
modification percentage at those sites can be calculated by comparing the amount of
modified proteins tryptic peptides containing lysine to those of unmodified proteins.
Enzyme catalyzed 18O labeling is a simple technique incorporating a maximum of two 18O
atoms at the C‐terminal carboxyl group of proteolytic peptides in the presence of H218O.
This results in a mass shift of 4 Da between

18

O/16O labeled peptides, thus, enabling

peptides quantitation. The 18O based method has proved to be a useful tool not only for
protein quantitation in serum169 and tissues170 but also for quantitating changes of
protein phosphorylation (post‐translational modification).171 Despite the simplicity and
low costs, incomplete labeling, mostly due to the different enzyme substrate specificity,
oxygen back exchange, pH and peptide physicochemical properties (e.g. size, charge,
hydrophobicity…) make this method technically challenging. However, the problems can
be overcome either by using correction algorithms172 or by minimizing back exchange
i.e. decreasing the pH,173 using heat deactivated trypsin174 or using immobilized
trypsin175, 176.
5.2.

Materials and methods

5.2.1. Chemicals and Reagents.
H218O (97% purity) from Cambridge Isotope Laboratories (Andover, MA), iodoacetic
acid (IAA) and mass spectrometry‐grade trypsin were purchased from Sigma‐Aldrich
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Chemical Co. (St. Louis, MO, USA). All other chemicals and solvents used in this work
were of analytical grade or higher.
5.2.2. Preparation of SATA‐Lysozyme conjugate
Lysozyme (Lz) from chicken egg white (Sigma‐Aldrich, St. Louis, MO) was activated
by N‐succinimidyl‐S‐acetylthioacetate (SATA; Pierce Biotechnology, Rockford, IL) as
described in Nguyen et.al.,48. The reaction was carried out by incubating 200 µL
consisted of 50 µM Lz, 200 µM of SATA (freshly prepared in DMSO) in 50 mM phosphate
buffer with 100 mM NaCl pH 8.0 for 2h at 37oC. The control reaction was done in
parallel under the same conditions with DMSO added instead of SATA. Both control Lz
and SATA‐Lz conjugate were purified by size exclusion chromatography on a TSK Gel
3000 SWXL column (TOSOH Bioscience, King of Prussia, PA) using an Agilent 1100
(Agilent Technologies, Palo Alto, CA) HPLC system. The separation was performed in 150
mM ammonium acetate (pH 7.0) at a flow rate of 0.8 mL/min and was monitored with
280 nm UV detection. Protein concentrations were measured using a NanoDrop 2000c
(Thermo Fisher Scientific, Rockford, IL) UV‐Vis spectrophotometer.
5.2.3. Protein Digestion and Post‐digestion Labeling
Control Lz samples and SATA‐Lz conjugate (10µg) were reduced in 10 mM DTT, 15%
acetonitrile (ACN) in 100 mM ammonium bicarbonate, pH 8.0 for 1h at 60oC followed by
alkylation with 20 mM iodoacetic acid (IAA) for 45 min in the dark. Digestion was carried
out overnight at 37oC with sequence grade trypsin (1:30 protease/protein). The digested
samples were dried using the N2 purging method and then re‐suspended in 50 μL of
either H216O or H218O containing 10% DMSO, 0.3 µg trypsin and incubated at 37oC for 48
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hours. Samples were removed, vortexed, spun down and formic acid was added
immediately to make a final concentration of 1% (v/v) to quench trypsin activity. LC
MS/MS measurements were performed immediately and any remaining samples were
stored at ‐20oC.
5.2.4. Instrumentation.
Ion exchange chromatography of SATA‐Lz conjugate was performed on a 4.6 x 100
mm PolyCATA™ weak cation exchange column (5 µM, 300 Å, PolyLC Inc., Columbia,
16

MD). The

O/18O labeled mixtures of digested samples were subjected to LC/MS/MS

analysis on a PepMap100 75µm i.d. x 15cm capillary column using an LC Packings
Ultimate (Dionex/Thermo Fisher Scientific, Sunnyvale, CA, USA) nano‐HPLC system
coupled with a Qstar‐XL (AB SCIEX, Toronto, Canada) hybrid quadrupole/TOF MS. Steps
gradient. Post‐acquisition analysis of both SEC and MS data was carried out using Origin
8.0 (OriginLab Corporation, Northampton, MA) software.
5.3.

Results and discussion

5.3.1.

18

This

O method for quantitation of modification sites

18

O based method is first demonstrated for SATA‐Lysozyme (Lz) conjugate. Lz

was modified with SATA using a 4:1 SATA:Lz molar ratio. There are 7 possible
modification sites in Lz including six lysine residues (K1, K13, K33, K96, K97 and K116)
and the N‐terminus. ESI‐MS of the SATA‐Lz conjugate (+10 charge state) showed in
Figure 5.1 indicates that the most abundant product is a 1:1 conjugate, and up to three
SATA had been conjugated to Lz. The conjugate and control Lz were then subjected to
trypsin digestion followed by trypsin catalytic
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18

O labeling process as described in the

experimental section. The LC MS/MS measurements were carried out immediately after
mixing 16O labeled samples being unmodified or modified Lz with 18O labeled control Lz
as internal standard. Figure 5.2 shows all the tryptic peptides that are monitored in
order to quantitate lysine modification sites. The peptides coded CTx are control
peptides which neither include a lysine residue nor immediately follow a lysine residue
in the protein sequence. Whereas, Kx peptides (x is the location of lysine residue in Lz
sequence) are peptides directly related to the modification at location “x”. The
modification percentages at those lysine residues are proportional to the depletion of
corresponding peptides (Kx). Figure 5.3 indicates the

18

O labeled internal standard

strategy used to quantitate modification sites. Panel (A) shows the peptide MS1 spectra
of either

16

O (gray trace) or

18

O (black trace) labeled control Lz before and after 1:1

mixing (control mix). Since both samples are unmodified Lz, we expect to have the ratio
of 16O species (I0) to 18O species (I2 and I4) approximately 1.0. However, when mixing 1
to 1 ratio of 16O labeled modified Lz and 18O labeled control Lz, the 16O/18O ratio will be
less than 1 if there was a modification at adjacent lysine site (Panel B). The 16O/18O ratio
was calculated using the following equation adopted from Yao et. al.,177
 16 O 
ratio 18  
 O

I0
M 
M   
M  
M 
I 4   4  I 0  2  I 2   2  I 0    I 2   2  I 0 
M0 
 M0 
 M0   
 M0  

(1)

M0, M2, and M4 are the relative intensities for the first, third and fifth peak in
theoretical isotope pattern of peptides which can be calculated based on peptide

84

sequences using Analyst QS calculator tool; whereas I0, I2, and I4 are the observed
intensities from the 16O/18O peptides mixture.
Additionally, calibration plots were used in order to accurately quantitate
modification percentages. Standard samples were prepared by mixing

16

O and

18

O

labeled digested control Lz at various ratios being 1:1, 0.75:1, 0.5:1, 0.25:1, 0:1 (16O:18O).
Figure 5.4 shows calibration plots of monitored peptides. Although all of them have
good linearity; different peptides show different slopes and intercepts with the y axis.
The factors that could contribute to this issue include incomplete labeling, different
enzyme substrate specificity, oxygen back exchange, pH and peptide physicochemical
properties such as size, charge and hydrophobicity. After closely inspecting isotopic
distributions of labeled peptides, we realized that the observed isotopic patterns are
mainly due to the incomplete incorporation of 18O to a subset of peptides, not because
of oxygen back‐exchange. Subsequently, labeling conditions have been optimized in
order to overcome this insufficient labeling issue. However we can only manage to
minimize the process but not eliminate it. Others have tried to fix this issue. For
example, Bezstarosti et. al., has reported a two‐step

18

O labeling using immobilized

trypsin that helps to completely label 18O to peptides.175 Furthermore, it was found that
the hydrophobicity of long peptides, such as K96 and K97, makes them unstable in
aqueous solution (buffer A; 0.1% Formic acid) and renders peptides prone to either
aggregation or interaction with and retaintion by the silica capillary tubing. Therefore,
mixing the peptides in 10% DMSO or ACN and immediate measurements after mixing
are required for more consistent results.
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Selection of Reference Peptide. It is worth noting that lysines are among the most
abundant amino acids, e.g. 58 lysines in transferrin and ~90 lysines in a typical
monoclonal antibody; thus it is impractical to construct calibration plots and analyze all
of them. In fact, only one good reference peptide is needed for this method. The criteria
for selection of the reference peptide in this 18O based modification sites quantitation
are stability, labeling completeness and signal intensity. In order to find the best
reference, a group of ten peptides was investigated by comparing their 16O to 18O ratios
calculated from triplicate equally mixed control samples. Finally, CT3 (WWCNDDGR) was
selected as a reference since it can be easily and stably detected at a very low
concentration. More importantly, as shown in Figure 5.5, normalized 16O/18O ratios of all
peptides against the ratio of CT3, nearly all results were well within ±15% range of the
calibrated value.
A linear calibration curve of reference peptide CT3 was plotted from 0% to 100%
modification percentage using the measured

16

O/18O ratios versus the corresponding

mixing ratios being 1:1, 0.75:1, 0.5:1, 0.25:1 and 0:1 (16O:18O) (Figure 5.6). Triplicate
measurements were conducted for each data point, and the standard deviation was
presented as the error bar. This calibration plot was then used to quantitate the
modification percentage at different lysine sites. Figure 5.7 shows modification
percentages at all six lysine sites along with measured control peptide percentages (gray
bars) for method validation purposes. Blue bars correspond to SATA modified to Lz with
the molar ratio of 4 to 1 (SATA:Lz), while Red bars correspond to 8:1 SATA:Lz molar ratio
reaction. Triplicate measurements were conducted for each sample, and the standard
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deviation is presented as the error bar. Importantly, the percentages of all control
peptides were found in the range of the method error. Although two different peptides
were used to quantitate modification at K33, they showed similar results with the error
within ±15%. Moreover, the large error showed at K96 was due to instability observed
for the peptide used to quantitate that site. Of all the modification sites quantitated, we
found that the following order for the extent of modification: K97  K33 > K116  K13 >
K1(‐NH2)  K96. It is worth noting that,

18

O method can only be used to quantitate

modification of lysine side chain (‐NH2), it cannot measure the modification at the N‐
terminus. In order to correlate the relative reactivities of lysine SATA modification with
structural parameters of lysozyme, quantitation results were compared to predicted
surface accessibility (SA) and pKa values of lysozyme (4QEQ) (Table 5.1). It was found
that reactivities correlate more with the SA values than pKa. The high modification
percentage of K97 corresponds to its highest accessibility (53%) whereas K96 shows low
reactivity and lowest SA value (26%).
5.3.2. Comparison of
quantitation

18

O method and XIC estimation method for modification sites

To further evaluate the validity of this method, the results were compared to those
of the extracted ion chromatograms (XIC) estimation method. The reactivities of lysines
were calculated using following equation:
Reactivity %

∑ Area of all modified peptides containing lysine X
x100
∑ Area of all peptides containing lysine X
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(2)

While the XIC method is simple and very easy to use, it suffers from fundamental
errors. First of all, SATA replaces positively charge group of primary amine by its neutral
molecule, thus, modified peptides tend to have less charge than unmodified one. Figure
5.8 shows typical problems of XIC method when used for quantitation of modification
sites. Panel (A) shows +2 charge state of modified and unmodified K97 peptides with the
modification percentage calculated to be ~84%. However, reactivity calculated for the
same peptides at +3 charge state was only ~11% (Figure 5.8 B). This problem would be
less significant if the linker had a charge group similar to primary amine it replaced.
Second, very long peptides shown in Figure 5.8 D tend to have much lower intensity
than shorter ones. Therefore, if equation (2) is used, the calculated value is not
accurate. It is noticed that this problem only occurs with long peptides so a combination
of two or three enzymes would make peptides shorter, thus, the problem could be
solved. Despite all those problems, XIC method is still a quick, useful tool for semi‐
quantitating modification sites of protein drug conjugate.
Figure 5.9 shows results from two methods. Panel A shows data from 4:1 SATA:Lz
modification while Panel B shows data from 8:1 SATA:Lz modification. Blue bars show
results from

18

O method while red bars indicate XIC results. The results from two

methods appear to agree with each other except for the K33 where XIC method over
estimates due to the calculation based solely on the long peptides. Additionally, XIC
method shows results for both lysine‐1 side chain and N‐terminus modification whereas
18

O only show reactivity for lysine side chain, thus higher percentage at K1 is expected in

XIC method. Although N‐ terminus is partially shielded by Thr‐40178 and has low
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accessibility, moderate reactivity at this site can be explained by its nucleophilicity
(pKa~9.0) and/or a possible conformational change upon modification of Lys‐1. These
results have proved that

18

O labeling method is a universal tool and can be used for

quantitating lysine based modification, despite the fact it lacks information about any N‐
terminus modification. This method can serve as a complementary method to XIC
estimation for more accurate quantitating reactivities of lysine side chains.
5.4.

Conclusions

Although heterogeneity of conjugation sites is usually the most difficult to
characterize, we have demonstrated 18O labeling method is a simple and cost‐effective
way of quantitating lysine modification sites of protein drug conjugates. It quantitates
the depletion of lysine‐adjacent peptides based on the fact that trypsin cannot cleave at
modified lysines. Among factors affecting the accuracy of this method, incomplete
labeling is the major one that is very hard to eliminate. We found that reactivities
correlate more with the SA values than pKa. The high modification percentage of K97
corresponds to its highest accessibility (53%) whereas K96 shows low reactivity and
lowest SA value (26%).
A comparison between

18

O and XIC method has also been carried out. While XIC

method is simple and very easy to use, it suffers from a fundamental error namely
differences in ionization efficiency of modified and unmodified peptides. The results
from the two methods appear to agree with each other. Although the N‐terminus was
partially shielded by Thr‐40178 leading to low accessibility, moderate reactivity at this
site can be explained by its nucleophilicity (pKa~9.0) and/or a possible conformational
89

change upon modification of Lys‐1. The results have proved that

18

O labeling method

can serve as an alternative method to XIC estimation or iTRAQ for accurate quantitation
of modification sites of protein drug conjugates. Moreover, this method can also be
applied for the quantitation of lysine site chain modification by chemical probes
normally used to characterize protein structure, function, and ligand binding.
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TABLES
Table 5.1. Predicted Lysine Surface Accessibilities and pKa Values
Residue

Surface accessibilities, %

pKa

N‐terminus

4.1

9.0

Lys‐1

37.7

11.25

Lys‐13

36.8

11.60

Lys‐33

35.6

10.15

Lys‐96

26.0

10.15

Lys‐97

53.3

10.45

Lys‐116

52.1

10.17

Surface accessibilities and pKa values for pdb structure 4QEQ were calculated using
online software GETAREA and PROPKA 3.0.
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FIGURES

Figure 5.1. ESI‐MS of the SATA‐Lz conjugate (+10 charge state) SATA:Lz (4:1) molar
ratio.

Figure 5.2. Tryptic peptides that are monitored in order to quantitate lysine
modification sites
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Figure 5.3. 18O labeled internal standard strategy used to quantitate modification
sites. (A) peptide MS1 spectra of either 16O (gray trace) or 18O (black trace) labeled
control Lz before and after 1:1 mixing (control mix). (B) 16O labeled modified Lz (gray
trace) and 18O labeled control Lz (black trace) before and after 1:1 mixing (modified
mix).
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Figure 5.4. Calibration plots of monitored peptides.
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Figure 5.5. Normalized 16O/18O ratios of all peptides against the ratio of CT3

Figure 5.6. A calibration curve of reference peptide CT3 was plotted using the
measured 16O/18O ratios versus the corresponding mixing ratios.
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Figure 5.7. Modification percentages at all six lysine sites along with measured
control peptide percentages (gray bars) for method validation purposes. Blue bars
correspond to SATA modified to Lz with the molar ratio of 4 to 1 (SATA:Lz), while Red
bars correspond to 8:1 SATA:Lz molar ratio modification. Triplicate measurements
were conducted for each sample, and the standard deviation was presented as the
error bar.
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s

Figure 5.8. typical problems of XIC method when used for quantitating modification
sites. (A) +2 charge state of modified and unmodified K97 peptides with the
modification percentage calculated to be ~84%. (B) reactivity calculated for the same
peptides at +3 charge state was only ~11%.
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A

B

Figure 5.9. Results from 18O method and XIC method. (A) shows data from 4:1
SATA:Lz modification; (B) data from 8:1 SATA:Lz modification. Blue bars show results
from 18O method while red bars indicate XIC results.
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CHAPTER 6
SUMMARY AND FUTURE OUTLOOK
Mass spectrometry has already become an indispensable tool for facilitating all
stages of modern medicine development and their characterization. It can be applied for
a variety of tasks ranging from analyzing covalence structure, conformations and
protein‐receptor interaction to quantitative measuring biodistribution of protein
therapeutics. In this work, we have demonstrated the potential of ESI MS in this field by
providing invaluable information used for optimizing protein drug conjugate structures
during early stages of development, and further catalyzing the drug design efforts.
Importantly, this method can readily be applied to other protein drug conjugates
development such as antibody drug conjugates (ADCs).

Additionally, a new method based on metal tracers and (ICP) MS was developed in
our lab has been applied for ultrasensitive quantitation of exogenous Tf and Tf‐based
drugs in biological tissues and fluids. With this method, injected Tf and Tf‐based drugs
were successfully detected in the cerebrospinal fluid (CSF) in which proteomic 18O based
method developed in out lab fails. Furthermore, laser ablation (LA) ICP‐MS in
cryosections of organs of interest was also assessed. LA‐ICP‐MS have been
demonstrated its imaging capabilities for studying biodistribution of metal coded
protein drugs at cellular level. This is also a promising tool that can be applied for the
tracking of cancer‐targeting Tf conjugates delivery to tumor cells.
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Another application of ICP‐MS based method was also assessed. When combine to
separation methods such as SEC and CE, ICP‐MS with the help of a metal tracer becomes
a powerful detector for structural study of protein drugs. This method has been
successfully applied to probe into protein stability post‐injection and yields useful data
not accessible by other methods. It is the first time a small soluble protein aggregation
of injected protein drug was studied in live animals. It is speculated that the application
of ICP‐MS based method using metal tracer in combination with separation (SEC, CE) or
fractionation (FlFFF) techniques will prove to be a useful tool for probing protein
aggregation post‐injection.

Finally, a simple and cost‐effective 18O labeling‐based method has been developed
for quantitating lysine modification sites of protein drug conjugates and has been
successfully applied for SATA‐Lz conjugate. The results have proved that

18

O labeling

method can serve as an alternative method to XIC estimation or iTRAQ for accurate
quantitation of modification sites of protein drug conjugates. Moreover, this method
can also be applied for quantitating chemical probes modified lysine site chain in order
to characterize protein structure, function, and ligand binding.
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